

University of Groningen

Mesenchymal stromal/stem cells as potential therapy in diabetic retinopathy

Fiori, Agnese; Terlizzi, Vincenzo; Kremer, Heiner; Gebauer, Julian; Hammes, Hans-Peter; Harmsen, Martin; Bieback, Karen

Published in:
Immunobiology

DOI:
[10.1016/j.imbio.2018.01.001](https://doi.org/10.1016/j.imbio.2018.01.001)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Version created as part of publication process; publisher's layout; not normally made publicly available

Publication date:
2018

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Fiori, A., Terlizzi, V., Kremer, H., Gebauer, J., Hammes, H-P., Harmsen, M. C., & Bieback, K. (2018). Mesenchymal stromal/stem cells as potential therapy in diabetic retinopathy. *Immunobiology*. DOI: 10.1016/j.imbio.2018.01.001

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.



Contents lists available at ScienceDirect

Immunobiology

journal homepage: www.elsevier.com/locate/imbio

Review

Mesenchymal stromal/stem cells as potential therapy in diabetic retinopathy

Agnese Fiori^{a,1}, Vincenzo Terlizzi^{b,c,1}, Heiner Kremer^a, Julian Gebauer^a, Hans-Peter Hammes^b, Martin C. Harmsen^c, Karen Bieback^{a,*}^a Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, German Red Cross Blood Service Baden-Württemberg - Hessen, Germany^b Dept. Endocrinology, 5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Germany^c University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Lab for Cardiovascular Regenerative Medicine (CAVAREM), Groningen, The Netherlands

ARTICLE INFO

Keywords:

Mesenchymal stem cells
Adipose stromal cells
Diabetic retinopathy
Mode of action
Pericytes
Paracrine function
Immunomodulation

ABSTRACT

Diabetic retinopathy (DR) is a multifactorial microvascular disease induced by hyperglycemia and subsequent metabolic abnormalities. The resulting cell stress causes a sequela of events that ultimately can lead to severe vision impairment and blindness. The early stages are characterized by activation of glia and loss of pericytes, endothelial cells (EC) and neuronal cells. The integrity of the retinal microvasculature becomes affected, and, as a possible late response, macular edema may develop as a common reason for vision loss in patients with non-proliferative DR. Moreover, the local ischemia can trigger vasoproliferation leading to vision-threatening proliferative DR (PDR) in humans. Available treatment options include control of metabolic and hemodynamic factors. Timely intervention of advanced DR stages with laser photocoagulation, intraocular anti-vascular endothelial growth factor (VEGF) or glucocorticoid drugs can reduce vision loss.

As the pathology involves cell loss of both the vascular and neuroglial compartments, cell replacement strategies by stem and progenitor cells have gained considerable interest in the past years. Compared to other disease entities, so far little is known about the efficacy and potential mode of action of cell therapy in treatment of DR. In preclinical models of DR different cell types have been applied ranging from embryonic or induced pluripotent stem cells, hematopoietic stem cells, and endothelial progenitor cells to mesenchymal stromal cells (MSC). The latter cell population can combine various modes of action (MoA), thus they are among the most intensely tested cell types in cell therapy. The aim of this review is to discuss the rationale for using MSC as potential cell therapy to treat DR. Accordingly, we will revise identified MoA of MSCs and speculate how these may support the repair of the damaged retina.

1. Diabetic retinopathy

DR is a complex and multifactorial diabetic complication. Hyperglycemia, inflammation and neuronal dysfunction are the major

factors in the pathophysiology of DR but also systemic factors such as hypertension may be involved. A variety of biochemical pathways are affected as discussed in detail previously (Hammes et al., 2002; Hammes et al., 2011b; Stitt et al., 2016). Especially chronic

Abbreviations: AGE, advanced glycation end product; ALDH, aldehyde dehydrogenase; AMD, age-related macular degeneration; Ang-2, angiotensin 2; ASC, adipose tissue-derived stromal/stem cells; α -SMA, alpha-smooth muscle actin; BDNF, brain-derived neurotrophic factor; BM-MSC, bone marrow mesenchymal stem cells; BRB, blood retinal barrier; CB-MSC, cord blood mesenchymal stem cells; CO, carbon monoxide; CNTF, ciliary neurotrophic factor; DR, diabetic retinopathy; EPO, erythropoietin; EC, endothelial cells; ECM, extracellular matrix; GLO-1, methylglyoxal-metabolizing enzyme glyoxalase-1; GPx1-3, glutathione peroxidases; HGF, hepatocyte growth factor; HO-1, heme oxygenase 1; hRPCs, human retinal pericytes; IGF, insulin-like growth factor; IDO, indole amine 2,3-dioxygenase; IL, interleukin; INF- γ , interferon-gamma; ISCT, International Society for Cellular Therapy; imPSCsc, mouse induced pluripotent stem cells; iPSCs, induced pluripotent stem cells; EAU, experimental autoimmune uveitis; ECM, extracellular matrix; ET-1, endothelin-1; FGFb, fibroblast growth factor b; MSC, mesenchymal stromal/stem cells; MCP-1, monocyte chemoattractant protein 1; MIF, macrophage inhibitory factor; CI, mitochondrial complex one; MMP, matrix metalloproteases; MoA, mode of action; NG2, neural/glia antigen 2; NGF, nerve growth factor; NO, nitric oxide; NOX, NADPH oxidase; NT3, neurotrophin-3; NOTCH, neurogenic locus notch homolog protein; OIR, oxygen-induced retinopathy; PDGF-B, platelet-derived growth factor B; PDR, proliferative diabetic retinopathy; PEDF, epithelial derived growth factor; PGE2, prostaglandin E2; PKC, protein kinase C; RAGE, receptor for advanced glycation end products; RGS5, regulator of G-protein signaling 5; ROS, reactive oxygen species; SOD, superoxide dismutases; SVF, stromal vascular fraction; STZ, streptozotocin; T1D, type 1 diabetes; T2D, type 2 diabetes; TGF- β , transforming growth factor beta; Th, T helper; TNF- α , tumor necrosis factor alpha; Treg, regulatory T cell; TRX, thioredoxin reductases; VEGF, vascular endothelial growth factor

* Corresponding author at: Friedrich-Ebert Str. 107, 68167, Mannheim, Germany.

E-mail address: Karen.bieback@medma.uni-heidelberg.de (K. Bieback).

¹ Both authors contributed equally.

<https://doi.org/10.1016/j.imbio.2018.01.001>

Received 3 August 2017; Received in revised form 13 December 2017; Accepted 15 January 2018

0171-2985/© 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

hyperglycemia appears as the initiator of a vicious cycle of events by inducing biochemical abnormalities in target tissues of diabetic complications through mitochondrial overproduction of reactive oxygen species (ROS) (Brownlee, 2005). Mechanisms, which lead to ROS production, are at least: increased polyol pathway flux, increased formation of advanced glycation end products (AGEs), activation of protein kinase C and increased hexosamine pathway flux. The resulting oxidative stress induces injury to all cell types in the retina. Pericytes appear to be the first cell type affected, then endothelial cells vanish leaving nonperfused acellular capillaries (Hammes et al., 2011a). This vasoregression is accompanied by neuronal damage affecting the neurovascular unit and the blood-retina barrier. The proliferative stage is caused by severe retinal ischemia, uncontrolled expression of pro-angiogenic factors and endothelial cell proliferation leading to severely hyperpermeable and rupture-prone vessels. Inflammatory processes play an important additional role. Inflammatory cytokines are produced by a variety of cell types under hyperglycemic and hypoxic conditions including glial and microglial cells (Vujosevic and Simo, 2017).

The disease can progress from a mild form of non-proliferative disease, marked by microaneurysms in the retina to severe stages, denoted by intraretinal hemorrhages, venous beading and intraretinal microvascular abnormalities (Stitt et al., 2016) (Fig. 1). Tight glycemic control can significantly reduce the risk and progression of DR in early stages (Aiello and DCCT/EDIC Research Group, 2014). In patients with type 1 diabetes (T1D), renin-angiotensin system inhibitors are now standard therapy if incipient diabetic nephropathy coincides. Evaluating the progression of DR in patients requires non-invasive methods. The first and most important method is funduscopy with and without permanent documentation by photography. Funduscopy focusses

mainly on the detection of the main diabetes-related vascular pathologies, *i.e.* progressive vasoregression and increased vascular permeability (Williams et al., 2004). This is complemented by optical coherence tomography, which enables the identification of retinal degeneration, of macular edema and of inflammatory cell invasion (Virgili et al., 2015). Not widely used techniques like ultra-wide field imaging can assess important morphological changes in the peripheral retina and give clues on the severity of DR (Soliman et al., 2012). Finally, sensitivity of cells constituting the neuroretina layer is measured by multifocal electroretinogram (ERG) (Harrison et al., 2011). Abnormality in cells' electrical signals may precede the development of retinal lesions and microaneurysms in some, but not in all cases (Santos et al., 2017). Furthermore, regular screening for clinical signs of DR helps to control disease progression and can reduce the risk of vision loss by enabling timely intervention with laser photocoagulation or intraocular drug injection (anti-VEGF or glucocorticoids) (DCCT/EDIC Research Group et al., 2017). Beneficial effects of these therapies do not affect to all patients, may be only transitory, or can have adverse side effects. Therefore, the clinical use is limited and new treatment strategies are needed.

The majority of established therapies target quite advanced states of DR. It is desirable to develop strategies which target early phases in DR to delay or even prevent DR. Cell-based therapies may offer direct tissue replacement and/or endogenous regeneration *via* trophic paracrine factors. Besides MSC, endothelial progenitor cells (EPC)/endothelial colony forming cells and pluripotent embryonic or induced pluripotent stem cells (iPSC) have been tested (Park, 2016).

Due to their broad mechanisms of action, involving secretion of trophic factors, similarity to pericytes, extracellular matrix (ECM)




Fig. 1. Diabetic retinopathy (DR) is a multifactorial microvascular disease that is caused by chronic hyperglycemia and subsequent adverse metabolic sequelae. The resulting cell stress causes a series of events which may lead to severe vision impairment and blindness ultimately. The early stage of DR is characterized by activation of glia and loss of pericytes, endothelial cells (EC) and neuronal cells. The integrity of the retinal microvasculature is negatively affected while a late response may comprise the development of macular edema in non-proliferative DR. Alternatively, DR may proceed towards so-called proliferative DR. This is induced by the local ischemia which is a strong pro-angiogenic trigger that causes abnormal capillary growth, intraretinal hemorrhages and the formation of cysts among others. Together, this is the leading cause of deteriorated vision and blindness in diabetics.




Fig. 2. Proposed mechanism of action (MoA) of MSC in DR. Thick arrows indicate MoA based on the use of MSCs in preclinical models of DR (see also Table 2). Dotted arrows indicate known MoA based on diabetes studies at a systemic level, but not explicitly in DR (requires confirmation in (pre)clinical models). Regular arrows indicate hypothesized MoA, based on the use of MSCs in other than diabetic diseases, which however have not been described in DR until now.

modulation, ROS scavenging potential and finally immune modulatory capacities, MSC may affect DR disease progression at different disease stages from vasoregression to vasoproliferation (Fig. 2).

2. Animal models of DR

Firstly, rodents represent a valuable animal model to investigate the impact of cell therapy in DR because of their short life cycle and responsiveness to genetic manipulation. Secondly, the use of streptozotocin (STZ), specifically toxic to β cells in the pancreas, induces reproducible severely hyperglycemic conditions mimicking essential features of the human disease. STZ causes destruction of the pancreatic islet and, subsequent hypoinsulinemia and hyperglycemia (Rossini et al., 1977). In the retina, early signs of DR corresponding to pre-clinical human disease stages are evident, *i.e.* loss of pericytes, vasoregression, neurodegeneration and glial activation (Hammes, 2018). There are several other animal models with different characteristics and dynamics, such as the Ins2Akita (Akita) mouse model which holds a mutation in the gene encoding insulin-2 causing spontaneous diabetes (Barber et al., 2005).

It has to be noted that the current animal models can only serve as models for incipient DR as none of the animals develops PDR. In order to obtain a mouse strain with PDR, transgenic mice, in which the bovine rhodopsin promoter is coupled to the gene for human VEGF, have been crossed with Akita mice (Okamoto et al., 1997). The hybrid, named Akimba, shows several signs of PDR such as microaneurysms, leaky capillaries, and capillary dropout (Rakoczy et al., 2010). Finally, the angiogenic aspects of PDR can be simulated by exposing mice to hyperoxia resulting in retinal ischaemia followed by proliferative vascular damage in the retina layers (oxygen-induced retinopathy (OIR) (Smith et al., 1994). These are the main animal models which resemble a general frame of diabetic driven complication in the eyes.

3. Mesenchymal stromal cells: a brief overview

MSC were first described by Friedenstein in 1970 as fibroblast colony-forming cells, isolated from bone marrow, with osteogenic differentiation potential. It is noteworthy to emphasize that Friedenstein himself, already at their first description, introduced them as new “therapeutic” component to be considered in bone marrow transplants (Friedenstein et al., 1970).

After their first description MSC were widely studied, bringing new insights regarding their biology and functions. Moreover, different sources of MSC were found beyond bone marrow (BM-MS) such as adipose tissue (adipose tissue-derived stem/stromal cells – ASC) (Bajek et al., 2016; Kern et al., 2006), dental pulp (Perry et al., 2008), cord blood (CB-MS) (Bieback et al., 2004) and Whartońs jelly (WJ-MS) (Joerger-Messerli et al., 2016). However, at the same time, misconceptions about MSC were arising, limiting their applicability in therapeutic approaches (Phinney and Sensebe, 2013). The message of the authors is: a) MSCs differ based on their tissue origin and b) when isolated from different organisms, c) MSC are heterogeneous, d) the current panel of surface “markers” is insignificant for function, e) MSCs function *in vitro* may/will differ from their *in vivo*, thus f) only clinical data will be able to give insight into the actual mode of action.

In this context, at least minimal criteria regarding MSC characterization were proposed by the International Society for Cellular Therapy (ISCT). Following ISCT guidelines, MSC are defined as multipotent progenitor cells with a fibroblast-like, spindle shape morphology and a robust proliferation capacity. They possess a strong plastic adherence, and trilineage mesenchymal differentiation potential (adipocytes, osteoblasts and chondroblasts) as well as a panel of surface antigens that define their phenotype (Dominici et al., 2006). In the meantime modifications of these criteria have been agreed on to characterize MSC from other tissue sources, *e.g.* ASC (Bourin et al., 2013).

Table 1
Main MSCs trophic mediators.

Growth factor	Receptors	Some functions
FGF (FGF1-24) (Fibroblast growth factor)	FGFR1-4	Reported as a mitogen. Regulates and induce angiogenesis. Involved in to inflammatory and immune responses.
VEGF (Vascular endothelial growth factor)	VEGFR1, VEGFR2	One of the key regulators of angiogenesis. Inhibits apoptosis. Activate protein kinases activity.
NGF (Nerve growth factor)	Trk A	Maintenance and growth of some neurons.
BDNF (brain-derived neurotrophic factor)	Neurotrophin TRKB	Positive regulation of sprouting. Regulation of proteins on cell surface. Cell-cell signaling.
GDNF (glial-derived neurotrophic factor)	<i>i.e.</i> Toll-like receptor binding	Regulation of stem cells differentiation. Regulation of gene expression.
CNTF (ciliary neurotrophic factor)	Interleukin-6 receptor binding	Regulates retinal cells apoptosis. Signal transduction. Positive regulation of cells proliferation.

Interest in MSC as therapeutic cells has been steadily increasing, supported by an improved understanding of their functions and properties. In addition, their beneficial behavior in contexts of different diseases such as graft *versus* host disease (Le Blanc et al., 2004, 2008), wound healing processes (Gaur et al., 2017; Kim et al., 2017), tumors (Blogowski et al., 2016; Cammarota and Laukkanen, 2016; Koliarakis et al., 2017), and autoimmune diseases (Pistoia and Raffaghello, 2017; Tyndall, 2008) has been documented. Taking into account the multiplicity of studies and diseases in which MSC treatment has been applied, at least three mechanisms can be considered predominant in the MoA of MSC in a disease context.

First and most documented MoA is represented by the paracrine and trophic potential. MSC, in fact, are able to secrete a broad range of growth factors that can modulate their surrounding microenvironment, favoring cell-cell interaction and communication with different cell types (Salgado et al., 2010).

Secondly, MSC retain an immunological profile that makes them hypo-immunogenic. Because of low surface expression of HLA class I, inducible HLA-class II expression and the lack of costimulatory molecules such as CD40, CD80 and CD86 they may survive in an allogeneic environment (Haddad and Saldanha-Araujo, 2014). In addition, MSC are strong immunomodulators (Najar et al., 2016). Immunomodulation can be mediated by both cell-cell interaction and the release of soluble factors. The most reported mechanism is the MSC-mediated inhibition of T-cell proliferation, and the promotion of a regulatory T-cell subpopulation (Treg) (Haddad and Saldanha-Araujo, 2014; Luz-Crawford et al., 2013). However, MSC can interact also with B-cells, natural killer cells, monocytes/macrophages and dendritic cells. The production of immunoregulatory factors such as TGF- β , HGF, prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO) and nitric oxide (NO) has been widely documented in several studies and directly sustains their immunological potential (Yan et al., 2014a; Yang et al., 2009).

Lastly, MSC have a differentiation potential that is clearly related to their multipotency. This potency would enable them to differentiate towards the damaged or lost cell types in order to replace cells at least transiently at the site of injury. However, the understanding of the underlying mechanisms of homing, proliferation, differentiation and functional engraftment of MSCs is in its infancy, in particular with respect to treatment of DR. The mere fact that *e.g.* in rodent models for retinal injury, MSC co-localized with and acquired neuronal and glial markers (rhodopsin resp. GFAP) or pericytic markers (Rajashankar, 2014; Mendel et al., 2013) does confirm that the respective functions were acquired too after intravitreal administration. Cell fusion may have happened resulting in co-expression of different marker molecules (Park, 2016; Tomita et al., 2002).

These combined functions render MSC one of the most interesting and promising tool for a potential therapeutic cell based approach for a number of diseases.

4. MSC for DR treatment – potential modes of action

Given the potential of MSCs and the characteristics of early DR in models, the promotion of cell repair and the defense against stress cell damage evolves as experimental focus. The functional restoration of

damaged tissue by repair or regeneration can be accomplished by stem cells in three ways or a combination. Firstly, stem cells are constructive *via* their differentiation and engraftment into tissue. Secondly, stem cells are instructive which means that *via* the secretion of trophic factors, stem cells direct the local microenvironment to a proregenerative state. Thirdly, stem cells may act in a reconstructive manner *via* the remodeling of the extracellular matrix (ECM) by secretion of *e.g.* matrix metalloproteinases (MMPs) and a host of structural (ECM) proteins. The reconstructive function of, in particular MSC, is frequently neglected, but it should be noted that the ECM is the prime extracellular reservoir of growth factors as well as of diabetic triggers for inflammation (AGEs).

4.1. MSC as trophic mediators

MSC are well known to secrete a broad range of pro-regenerative, mitotic, angiogenic, anti-apoptotic, anti-fibrotic factors, such as basic fibroblast growth factor (bFGF), VEGF, insulin-like growth factor (IGF), HGF, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), ciliary neurotrophic factor (CNTF) (Table 1) (Caplan, 2008; Ezquer et al., 2014; Griffin et al., 2016). These factors appear to modify the local microenvironment from an adverse injury to a pro-regenerative milieu. In addition to secreted growth factors, cytokines and chemokines, which will be influential, but most likely in local distance and short-lived, MSC are able to pack trophic mediators into extracellular vesicles (exosomes, microvesicles) (Doepfner et al., 2015; Ophelders et al., 2016). These extracellular vesicles cannot only transport proregenerative factors, but also mRNA and microRNA but even mitochondrial components over a long distance (Rani et al., 2015; Yanez-Mo et al., 2015).

It is not yet clarified whether these trophic functions require MSC to home and engraft to the sites of injury as there are also indications that conditioned medium, extracellular vesicles or other shuttled factors have been functional (Gao et al., 2014; Nagaishi et al., 2016; Park et al., 2010). Migration to pancreatic islets or organs suffering from diabetic complications has been shown (Lee et al., 2006; Sordi et al., 2005). Tissue regeneration, revascularization and sustained normoglycemia were achieved. In NOD-SCID and STZ diabetic mice MSC injection restored glycemia by increasing β cell mass and promoting renal protection (increased proliferation, decreased apoptosis, increased levels of proregenerative factors, and anti-inflammatory cytokines, decreased macrophage infiltration and oxidative stress damage) (Ezquer et al., 2015, 2008). Priming of MSC appears to even further improve these effects (Xu et al., 2009). MSC, genetically-engineered to express VEGF or pancreatic-duodenal homeobox 1 (PDX-1), improved survival and reversed hyperglycemia. The effect, however, was only sustained when injecting VEGF-MS and involved recovery of β cell mass (Milanesi et al., 2012).

In models of diabetic neuropathy, MSC have been shown to act *via* induction of neurotrophic factors, *e.g.* NGF and neurotrophin-3 (NT-3). Both were significantly increased 2 weeks post-infusion, but no more 4 weeks post-infusion (Kim et al., 2011). A recent study indicates that MSC injection in diabetic neuropathy has additional effects by reducing inflammatory cytokines, apoptosis, calcium and ROS levels (Osés et al.,

2017).

To date, the trophic mode of action of proangiogenic MSCs appears paradoxical, in particular with respect to DR in which angiogenesis should be dampened or normalized instead of promoted. The caveat in this reasoning, is that MSCs secrete a plethora of paracrine factors, that partly have opposite functions, while MSCs may act to normalize aberrant microvasculature *via* juxtacrine mechanisms too (described in the next section). Nevertheless, a number of factors secreted by MSC and exerting proregenerative functions in other disease modalities may have adverse effects in DR. Many of these factors, in fact, are considered as biomarkers for DR and have been attributed to disease progression. VEGF, for instance, is a target of therapeutic interventions in DR. There is evidence that anti-VEGF antibodies (bevacizumab, Avastin or ranibizumab, Lucentis) have protective effects and can slow down disease progression (Li et al., 2017b; Martinez-Zapata et al., 2014). These anti-VEGF-A antibodies recognize all isoforms of VEGF, although it might be advantageous in the future to target only those specific isoforms known to cause trouble. For instance, a recent study addressed the expression of the two isoforms of VEGF, VEGF_{165a} and VEGF_{165b}, considered to represent pro- or anti-angiogenic VEGF, and their receptors in plasma of patients with DR, with diabetes or controls (Paine et al., 2017). With increasing disease stages, VEGF_{165a} and VEGFR-2 concentrations were increased. A variety of other intravitreal growth factors, cytokines and chemokines have been attributed to disease progression and considered as potential biomarkers or even as therapeutic targets. However, it has to be taken into account that vitrectomy is only performed in only a minority of patients and mostly at severe disease stages and that thus samples might be contaminated with serum/plasma proteins, especially in severe disease stages (Abcouwer, 2013). Similar to VEGF, further angiogenic factors such as angiopoietin-2 (Ang-2), osteopontin, PDGF, erythropoietin (EPO), stromal cell derived factor 1 (SDF-1) have been found to be increased, and vice versa anti-angiogenic factors decreased, such as pigment epithelium derived growth factor (PEDF), endostatin, angiostatin and tissue kallikrein (reviewed in (Abcouwer, 2013)). A recent meta-analysis identified VEGF, IL6, IL8, EPO, PDGF-BB, NO, endothelin-1 (ET-1), monocyte chemotactic protein 1 (MCP-1), TGF- β , and TNF- α to be increased in the vitreous of patients with proliferative DR independent of T1D or T2D. PEDF and HGF were decreased (McAuley et al., 2014). In this meta-analysis, VEGF was the only biomarker which was able to significantly discriminate patients with and without nonproliferative DR. Since a variety of these molecules have dual functional roles, the may not only represent disease but also the attempt to regenerate injured tissue. IL6, for instance, is considered as proinflammatory molecule but it is known to orchestrate functions, not only in the immune system, but also in the nervous system. Here it can increase inflammation and thus tissue damage, but acting as neurotrophin it can also support neuronal regeneration (Suzuki et al., 2009).

Because DR is a multifactorial and multistep disease, protection or slow-down of progression requires a well-orchestrated milieu balancing intrinsic repair attempts against adverse stress events promoting injury. MSC are highly plastic and adapt their repertoire of secreted factors, to cues of the local microenvironment (Phinney, 2007). Accordingly, these cells secrete a variety of factors, which are considered to contribute to DR progression, MSC may assist to change track from a vicious cycle to a proregenerative response.

4.2. MSC to act as pericytes

Pericytes are cells that wrap around microvessels throughout the body and which are of mesodermal origin. Ever since the first light microscopy studies in the late 19th century, little has changed on this description. In a landmark publication, Zimmermann published detailed light microscopy studies on pericytes and their intimate contact with capillaries (Zimmermann, 1923). Currently, the working definition of a pericyte is a (peri)vascular, basement membrane-embedded cell (Sims, 1986). In the microvasculature three types of contractile

perivascular cell types, pericytes, smooth muscle cells and supra-adventitial stromal cells appear to form a continuum of cell types that can (trans)differentiate into each other and which may be derived from a common CD146⁺ endothelial precursor (Zimmerlin et al., 2013). This high plasticity and the lack of definitive pericyte markers, as well as rapid phenotypic changes *in vitro*, render ‘pericytes’ a heterogeneous population at best (reviewed in Armulik et al., 2011).

Pericyte loss is considered a key event in the initiation of vasoregression (Hammes, 2005). Very recently it has been shown that selective pericyte loss is not enough to mediate blood retinal barrier (BRB) disintegration. However, loss of pericyte coverage sensitizes retinal vascular EC to VEGF-A. *Via* FOXO1 this leads to Ang-2 upregulation and triggers a positive feedback loop as seen in the pathogenesis of DR (Park et al., 2017).

MSC share several features with pericytes, such as their morphology and function but also their anatomic localization as perivascular cells. It was long debated which *in situ* origin MSC may have and where these are localized. Crisan et al. documented that in a magnitude of tissues MSC derive from a perivascular origin (Crisan et al., 2008). These data suggest that pericytes might be the *in vivo* progenitor of MSC (Caplan, 2008, 2017). Recent data however, challenge this idea. Guimaraes-Camboa et al. used lineage tracing of pericytes/smooth muscle cells expressing the transcription factor Tbx18 to demonstrate that perivascular cells do not behave as tissue-specific progenitors in various organs, neither in aging nor in pathological settings (Guimaraes-Camboa et al., 2017). Tbx18 cells kept their identity and failed to differentiate to other cell types. Sorted *in vitro* cultured Tbx18 pericytes, however, showed MSC potential, such as phenotype and differentiation potential. In line with this, a variety of data indicate that pericytes can be differentiated out of cultured MSC. In a recent systematic review Xu et al. compared protocols from 20 reports (Xu et al., 2017). The markers most commonly used to identify pericytes were PDGFR- β , alpha-smooth muscle actin (α -SMA), neural/glia antigen 2 (NG2), desmin and regulator of G-protein signaling 5 (RGS5) (Diaz-Flores et al., 2009). However, expression patterns on pericytes *in vivo* can differ at different developmental stages and in different tissues and organs. Accordingly, a combination of phenotypic markers, perivascular location, morphology, and functionality shall be used to define pericyte identity. These are all animal-based results; thus, the translation to human clinical applications warrants caution.

ASC have been shown to differentiate to pericytes *in vitro* and *in vivo*. Based on surface markers, the group of Bruno Peault classified adipose tissue derived MSC into two major groups: CD31-/CD45-/CD34+/CD146- cells (adventitial stromal/stem cells [ASC]) and CD31-/CD45-/CD34-/CD146+ cells (pericytes [PCs]). Using single-cell quantitative polymerase chain reaction they recently showed that aldehyde dehydrogenase (ALDH) activity can identify subclasses. ALDHbright-ASC were classified as the most primitive cells, followed by ALDHdim-ASC, ALDHbright-PC and finally ALDHdim-PC as least primitive, suggesting ASC at the basis of the differentiation hierarchy (Hardy et al., 2017; Herrmann et al., 2016). Transcriptomic analysis of highly purified non-cultured adipose tissue derived cells support this notion that perivascular MSC are precursors of pericytes (da Silva Meirelles et al., 2016). One study performed a direct comparison of MSC and pericytes (isolated based on CD34+, CD146+ expression from adipose tissue and bone marrow and retinal and placental pericytes). This comparison revealed reduced proliferative capacity of pericytes. MSC markers were comparable and highly expressed on all cell populations (CD44+CD90+CD73+CD105+ expressed on at least 75% of all cells). Pericyte markers were highly variable, CD146+NG2+PDGFR β + on 1.3% and 3.6% of retinal and placental pericytes and 48% to 80% on bone marrow or adipose tissue-derived MSC and pericytes. Interestingly, PDGFR β expression appeared to be highly variant, but not discriminatory for MSC vs. pericytes (Herrmann et al., 2016). This study showed higher osteogenic but slightly reduced adipogenic differentiation potential of the CD34+, CD146+ sorted pericytes from

both tissues. Chondrogenic potential was only seen in cells from BM but reduced in the pericyte population. Angiogenic potential in a Matrigel tube formation assay did not reveal any differences between the different cells.

The large phenotypical and functional overlap with pericytes renders MSC an ideal candidate in the cure and/or prevention of DR (Traktuev et al., 2008). There are numerous indications that injected MSC acquire a perivascular fate within injured tissues. Examples for DR are given below. Of note, pericytes, also retinal pericytes, have been shown to exert immunomodulatory function such as MSC (Navarro et al., 2016; Tu et al., 2011). Loss of immunomodulatory functions by disappearance of pericytes may add to vasoregression by impaired control of immune responses (see below).

4.3. MSC to restore the extracellular matrix

It is well documented that hyperglycemia, e.g. AGE modification, leads to changes in the retina, including the extracellular matrix (ECM) composition, matrix metalloproteinase activity and basement membrane thickening (Hammes et al., 1996; Yang et al., 2007). Resulting changes of interaction of EC and pericytes, as well as induced apoptosis, can lead to abnormal function, pericyte migration, endothelial cell apoptosis and finally increased permeability (Preissner et al., 1997). Since pericytes and EC are important components of the neurovascular unit, this is likewise affected causing disruption of the BRB.

The basement membrane is mainly composed of laminin, collagen type IV, fibronectin as structural components and proteoglycans such as perlecan and nidogens 1 and 2. It allows cell attachment and binds growth factors. Especially the heparan sulfate attached platelet derived growth factor (PDGF) appears to be relevant for the maintenance of cell-cell/cell-matrix interaction. PDGF is required for the BRB formation by recruiting pericytes and inducing their maturation (Park et al., 2017).

ECM degradation is required for vessel sprouting, thus there is a tight regulation of expression of matrix metalloproteinases (MMPs) and their inhibitors (van Dijk et al., 2015). In mesangial repair MSC have been shown to reverse the alterations of ECM proteins and by this contribute to repair (Herrera et al., 2016).

Furthermore, glycated matrix can trigger inflammation. AGEs are sensed by the receptor for advanced glycation endproducts (RAGE). RAGE activation results in pro-oxidant and pro-inflammatory pathways and an activation of the innate immune system additionally contributing to the vicious cycle of vasoregression (Zong et al., 2010). In a hyperoxia-induced lung injury model, MSC reduced signs of damage, associated with reduced RAGE/NF κ B expression and TNF- α secretion, suggesting an impact on RAGE/NF κ B signaling (Tian et al., 2013). AGEs can affect MSC (Kume et al., 2005; Stolzing et al., 2010; Aikawa et al., 2016). However, COMP-Ang, a chimeric form of Angiopoietin1 fused to the coiled-coil domain of rat cartilage oligomeric matrix protein, prevented negative effects of AGEs and improved viability and differentiation properties (Kim and Kwon, 2013).

4.4. MSC as scavengers of reactive oxygen species

Molecular oxygen acquires oxidant property if an unpaired electron is excited and changes its spin. Several molecules and free radicals derive from the reduction of oxygen, these molecular modifications are defined as ROS (Liochev and Fridovich, 1999). If the cellular metabolic pathways involved in ROS detoxification are impaired, oxidants indiscriminately react with proteins and DNA (Turrens, 2003). Cellular oxidative stress may originate from mitochondria via dysfunction of the electron transport chain or from the cytoplasm via NADH-oxidases (Nox) among others. Pathways that further dysregulate ROS production include increased polyol pathway flux, increased AGE formation, and activation of protein kinase C (PKC) isoforms (Brownlee, 2000). Diabetes causes ROS accumulation with serious complications (Giacco and

Brownlee, 2010) including DR (Guzman et al., 2017; Kowluru and Chan, 2007; Kowluru and Mishra, 2015).

Obviously, the reversal of either retinal ROS production or the scavenging by ROS neutralizing molecules has been put forward in therapeutic context. Hyperglycemia-induced ROS, via the TGF- β -activated kinase 1 (TAK1) -NF κ B signaling axis, also perpetuates inflammation in cells (Morgan and Liu, 2011; Ajibade et al., 2012).

MSC are equipped with a full array of mechanisms that neutralize oxygen and nitrogen radicals. These include glutathione peroxidases (GPx1-3), thioredoxin reductases (TrxR1, TrxR2), and superoxide dismutases (SOD1, SOD2), as well as DNA repair systems (Ezquer et al., 2014; Valle-Prieto and Conget 2010). Several of these redox balancing systems, however, depend on co-factors e.g. supplementation of culture medium with selenium augments MSC's potential to scavenge radicals (Ebert et al., 2006). Despite built-in protective mechanisms, ROS may promote apoptosis (Hajmoussa et al., 2016) and senescence (Ko et al., 2012; Chen et al., 2017; Jeong and Cho, 2015) of MSCs *in vitro*. ASC from obese mice have severe mitochondrial dysfunction and increased ROS production (Pérez et al., 2015) which might compromise the use of ASC from adipose diabetics for cell therapy. NOX-induced ROS reduces the (longterm) proliferative capacity of ASC (Sela et al., 2015). On the contrary, anti-oxidant pathways e.g. regulated via Nuclear Factor E2-related factor (Nrf2) cross-talk with pro-inflammatory NF κ B signaling which balances ROS responses in ASC (Chen et al., 2017). Peterson and co-workers, report that acute hypoxic exposure of pro-inflammatory-primed (IFN γ) ASC, dramatically increased intracellular ROS, while longterm exposure render these ASC in a pro-angiogenic state (Peterson et al., 2011). Hypoxic preconditioning alone also promotes survival of MSC in a ROS-dependent fashion (Valle-Prieto and Conget, 2010). This suggests that ROS-based preconditioning of ASC is beneficial for cell therapy, provided the right timing and conditions are determined and selected. In fact, hypoxically preconditioned ASC, accompanied by increased intracellular ROS, promoted survival primary hepatocytes via extracellular matrix-derived signaling, more than via soluble trophic factors (Qin et al., 2015).

Yet, how does this affect the influence of MSC on exogenously produced ROS or on intracellular ROS production of target cells? For the past decade, results accumulated that MSC harbor anti-oxidative features in rodent models of diabetes, such as diabetic nephropathy, diabetic neuropathy and DR (Ezquer et al., 2015; Fang et al., 2012; Ho et al., 2012; Lv et al., 2014; Ren et al., 2013; Sukpat et al., 2013). For instance, conditioned medium from umbilical cord MSC (UC-MS) induced the production of anti-oxidant enzymes such as copper superoxide dismutase, zinc-superoxide dismutase, manganese superoxide dismutase, glutathione peroxidase and catalase by ROS-producing muscle cells (Park et al., 2016). In addition, oxidative stress provoked by hyperglycemia did not compromise the glucose uptake and only partly abrogated mitochondrial functionality of ASC (Hajmoussa et al., 2016). Furthermore, ASC capacity to function as vascular supportive cells was maintained. One of the strategies that MSC acquire to modulate oxidative stress might involve mitochondria transfer to target cells (Melcher et al., 2017). In this study, *in vitro* cultured fibroblasts deficient of mitochondrial complex one (CI) accepted MSC mitochondria. ROS could be further reduced by either treating MSC with TNF- α , or MSC conditioned medium.

The aforementioned studies did not directly evaluate the ROS metabolism in MSC *in vivo*. Reports which address the balance of ROS guided by MSC injection in animal models affected by DR are lacking. Li and co-workers showed a first strategy to attenuate ROS during retinal ischemia. In this study, MSC were engineered to overexpress heme oxygenase-1 (HO-1), which catalyzes heme to biliverdin, free iron, and carbon monoxide (CO) and alleviates the oxidative stress. A reduction in apoptosis caused by the activation of antiapoptotic proteins Akt-1 and Bcl-2 was observed (Li et al., 2017a). The intravitreal injection of ASC in the STZ-induced T1D mice suppressed oxidative damage in the retina, which indicates that ASC influence ROS levels directly or

indirectly (Ezquer et al., 2015).

Overall these studies showed that MSC are capable to regulate ROS production in a variety of target cells. The molecular mechanisms comprise direct regulation of ROS with anti-oxidant enzymes, normalization of mitochondrial function, reprogramming of glucose metabolism, upregulation of anti-oxidant signaling (Nrf2) as well as upregulation of MAP kinase signaling. In general, suppression of ROS coincides with suppression of a pro-inflammatory status of cells, although it may occur that inflammation is suppressed while ROS is maintained.

4.5. MSC to target inflammation

Chronic low-grade inflammation (also called paraflammation) appears to be involved in the pathogenesis of DR, however it is most likely not involved in incipient stages of DR (Karlstetter et al., 2015; Wang et al., 2014). Hyperglycemia and hypertension induce oxidative stress, apoptosis, fatty acid metabolism and AGE/RAGE interactions. Increased levels of pro-inflammatory mediators, such as IL1 α , IL1 β , IL6, IL8, MCP-1, TNF α , and IL18 and chemokines, such as CCL2, CCL5, CXCL8, CXCL10, and CXCL1 have been detected in the vitreous of patients with advanced DR and proliferative DR, correlated to increased VEGF concentrations (Murugeswari et al., 2008; Wakabayashi et al., 2010). Inflammasome activation has been observed both in patients with proliferative DR and in the STZ animal models (Capitao and Soares, 2016; Chen et al., 2017). Resulting macrophage/microglia activation and M1 polarization fosters endothelial, glial and neuronal stress and sometimes degeneration (Abcouwer, 2011; Ma et al., 2014). Modeling endothelial activation, in human umbilical vein endothelial cells, co-stimulated with hyperglycemia and high doses of palmitic acid, to mimic DR-associated glucolipototoxicity, UC-MSCs suppressed inflammation (An et al., 2016). Both NF κ B activation was suppressed as well as downstream activation of glucolipototoxicity-related TNF- α -induced protein 6 (TSG-6). The endothelial phenotype appeared restored, because tube formation was normalized, but unexpectedly endothelial ROS production was not affected (An et al., 2016). T cells may rather play a minor role for local activities, as they are typically not found as infiltrates. Nevertheless, there are some indications, that patients with advanced DR stages show changes in the balance of T helper cell cytokines in serum and vitreous. Furthermore, T cell infiltrates in vitreous of patients with proliferative DR have been observed (Capitao and Soares, 2016).

MSC have proven broad immunomodulatory potential in various disease entities involving inflammatory and immune processes. However, since inflammation and immune responses at different stages in the development and progression of DR may play a distinctive role, the functions of MSC in this respect remain open. As mentioned, animal models are limited in modeling all stages of the human disease and thus do not represent the late stage disease in humans. Nevertheless, we would like to speculate on possible contributions of MSC in inflammation and immune responses.

4.5.1. MSC and microglia

Microglia are the resident macrophages of the CNS in the retina. They become activated in the concourse of diabetes (Wang et al., 2014). This has been observed both in humans and in animal models. Plasticity is a very well-known property of macrophages. In fact, they are able to respond to changes in their microenvironment polarizing towards an M1 or M2 phenotype. M1 macrophages are playing the major role in inflammation; producing pro-inflammatory cytokines and a large quantity of NO, and triggering the activation of the Th1 mediated immune response. On the contrary, M2 macrophages possess an immunosuppressive phenotype correlated to the production of anti-inflammatory cytokines like IL-10 (Gordon and Martinez, 2010; Mantovani et al., 2002). It appears, that in early phases of DR, activated microglia are polarized towards an anti-inflammatory/tolerogenic M2 phenotype, whereas at later stages the balance changes towards pro-

inflammatory M1 phenotypes. Wang et al. identified CD74 as a microglia activation marker which increased upon both glucose and methylglyoxal administration in a rat model (Li and Lin, 2012; Wang et al., 2014). CD74 is involved in the formation and transport of MHC/HLA-class II molecules, and is thus important for antigen presentation. Furthermore, it acts as receptor for Macrophage Migration Inhibitory Factor (MIF). Recent data in glioma models suggest that tumor-secreted MIF acting on CD74-activated microglia promotes a shift towards M2 macrophages (Ghoochani et al., 2016).

So far there is no study published analyzing the interaction of MSC with retinal microglia in the context of DR. One study showed that MSC engineered to express CX3CL1 exert neuroprotective and immunomodulatory function in a model of light-induced retinal degeneration (Huang et al., 2013). Here microglia activation and migration was reduced in MSC-transplanted animals. Modulation of microglia activation has also recently been shown by Jaimes et al. Here, BV-2, a murine microglia cell line, and primary murine brain microglia were cultured with microvesicles obtained from MSC supernatant. LPS induced activation of microglia was prevented (Jaimes et al., 2017). This fits to own unpublished data analyzing the effect of human ASC supernatant on primary human macrophages (K. Widmann, unpublished). We observed a clear reduction of M1 in favor of a M2 polarisation. An elegant study conducted by Melief et al. showed how Treg induction (see below) may be dependent on the skewing of monocytes toward a M2 phenotype. They observed that Treg formation was increased in MSC-PBMC cocultures more than MSC-CD4⁺ cocultures, suggesting the involvement of monocytes in Treg induction. Analyzing the monocyte fraction of cocultures they found that: 1) MSC increased survival of monocytes towards M-CSF secretion and 2) monocytes from cocultures have a decreased mRNA expression of pro-inflammatory cytokines with a concomitant increase in mRNA expression of anti-inflammatory cytokines and CCL18. CCL18 turned out to be key cytokine in driving Treg generation, suggesting that the modulation of monocytes towards an M2 phenotype may be a crucial mechanism in MSC mediated Treg formation (Melief et al., 2013).

All these observations found a surprisingly confirmation in a murine animal model of allo- and autoimmunity in the eye. Although it does not belong to the specific topic of this review, we briefly summarize these data as they maybe informative for future studies applying stem cells in DR considering immunogenicity of transplanted cells. In fact, Ko et al. demonstrated that intravenous injections of MSC were able to protect from rejection of corneal allotransplantation and from an experimental autoimmune uveitis (EAU). In the corneal allotransplantation model, MSC prevented histological abnormalities and reduced pro-inflammatory cytokines in the eye. Similarly, in EAU, MSC injection reduced IL2, IL1 β , IL6 and TNF- α in the eyeball. A B220 + CD11b + monocyte population found in the lung as well as in blood, spleen and lymph nodes mediated these effects. In addition, increasing levels of Treg where found one day after MSC infusion, and lower level of Th1/Th17 cells were induced in coculture of B220 + CD11b + /CD4⁺ T cells. Collectively these results suggest that monocytes, which were primed by the infusion of MSC, were able to promote Treg proliferation and inhibit the pro-inflammatory phenotype of T cells. More interestingly, intravenous infusion of MSC induced-B220 + CD11b + cells were able to prevent corneal rejection and EAU as well, highlighting the fact that they are crucial in the MSC mediated tolerance (Ko et al., 2016).

4.5.2. MSC and T-cells

As previously introduced, MSC affect a variety of immune cells and appear to regulate immune responses in favor of a pro-regenerative rather than an adverse injury-response. It is highly speculative whether the MSC effects on T cell responses may contribute to therapeutic efficacy in DR, nevertheless, we will summarize the known and provide possible links to DR.

In diabetes there have been reports, that MSC can exert anti-diabetic effects by affecting T cells. An improvement in the Th1/Th2 balance,

decreased Th17 and increased Treg numbers have been reported in models of T1D (Bassi et al., 2012; Ezquer et al., 2012; Favaro et al., 2014). Volarevic et al. have shown a disbalance of T-cell derived IL-1 and its receptor antagonist (IL-1R α) as a cause of β -cell impairment in T2D. In a mouse model, the β -cell damage has been ameliorated by MSC-derived IL-1R α (Volarevic et al., 2010). Whether MSC-mediated modulation of the T helper cell balance could be a MoA in DR has not been investigated yet.

MSC exert a strong suppressive effect on T cell proliferation, when T cells are triggered by different mitogenic stimuli such as PHA or anti-CD3/anti-CD28 monoclonal antibodies (Mohammadzadeh et al., 2014; Nicola et al., 2002; Yan et al., 2014a). On the contrary, they seem to support their survival when T cells are in a quiescent state (Benvenuto et al., 2007). Mechanisms that regulate the interaction with T cells still need elucidation; however, many studies revealed that both cell-cell interaction and production of soluble factors may drive MSC immunomodulation (Haddad and Saldanha-Araujo, 2014). In co-culture with naïve or activated T cells, MSC inhibited T cell proliferation principally by soluble factors. In one study, MSC conditioned media led to a 2-fold increase in apoptosis, while direct contact with MSC caused cell arrest in G0/G1 phase. The major factors responsible for T cell anergy were IL-10 and IDO (Yang et al., 2009). Yan et al. reported MSC inhibition on activated T cells in both direct and indirect coculture system. Here, the axis PD-1/B7-H1 was partially involved in inducing T cell apoptosis, with a dispensable role of IL-10 and TGF- β in the up-regulation of PD-1 on T cells (Yan et al., 2014b).

Furthermore, MSC can affect the balance of T helper (Th) cell subsets Th1, Th2 and Th17 cells and can induce Treg cells (Maccario et al., 2005). Th cells have been classified into Th1 cells, which produce IL2 and IFN γ and are involved in cellular immunity; Th2 cells which produce IL-4, IL-5 and IL-13 and are involved in humoral immunity; and Th17 cells producing the proinflammatory cytokine IL-17. Treg are commonly described as a CD4+ CD25+ Foxp3+ cells capable of suppressing other immune cells (von Boehmer, 2005). They can originate from thymus as a mature subpopulation or be induced from a circulating naïve T cell population (Sakaguchi et al., 2008). Treg formation seems to be triggered more by soluble factors than cell-cell interaction. A tight balance between Th1/Th2 and Th17/Treg has to be maintained for homeostasis (Zhang et al., 2014). Generation of ASC-induced functional Treg was observed in coculture by Engela et al. and resulted to be IL-2 pathway-dependent (Engela et al., 2013). In another study, MSC derived PGE2 was involved in Treg generation, as a PGE2 inhibitor resulted in reduced Fox-P3 mRNA expression in CD4+ T cells (English et al., 2009). It has been shown that MSC are able to inhibit Th1 and Th17 differentiation, depending on the differentiation stage and coculture ratio (Luz-Crawford et al., 2013). High levels of PGE2, TGF β and IL-10 were found in coculture of MSC with differentiated CD4+ T cells, *i.e.* Th1 and Th17.

There are few indications that T cells may play a role in DR. There are no T cells in the retina, thus effects on T cells may be related to rather systemic (autoimmune) than local responses. Some studies report a dysregulated Th1/Th2/Th17/Treg balance in favor of a pro-inflammatory Th1 and Th17 cytokine profile in serum and vitreous of patients with proliferative DR (Cao et al., 2016; Takeuchi et al., 2015). One study analyzed Th1/Th2 cytokines in the serum of 25 healthy subjects compared to 35 T2D patients without DR and 30 T2D patients with DR. In patients with DR the Th1 cytokines IL-2 and TNF α were strongly upregulated, even stronger in the T2D without DR group. Th2 cytokines were lower in T2D patients with DR, whereas T2D patients without DR showed no difference to the control cohort (Cao et al., 2016). In another study, a pro-inflammatory skewed profile with expanded Th1/Th17 cells and reduced Treg has been observed. It correlated to an increased urine albumin:creatinine ratio indicative of diabetic nephropathy (Zhang et al., 2014). In an experimental model of STZ-induced diabetes, blockade of IL-23, a cytokine critical for survival and proliferation of Th17 cells, significantly improved structure and

tightness of the BRB (Xu et al., 2015). However, the impact of these findings for human disease are unknown, as this model never develops proliferative DR and has also no relevant BRB disruption compared with humans.

Interestingly Th1/Th2 cytokines have been related to angiogenesis, by either controlling it directly or indirectly by modulating other factors in the micromilieu (Naldini et al., 2003). Pro-inflammatory Th1 cytokines appear to be inhibitory to endothelial cell and vessel growth, whereas anti-inflammatory T cells appear to be positive regulators of angiogenesis. Since MSC have profound properties in restoring the Th1/Th2 Th17/Treg balance this may be a further mechanism linking immunity and angiogenesis. This notion is supported by a very recent publication documenting that in fact Tregs are transiently recruited to the retina in neovascular retinopathy in an attempt to repair the vasculature. Expanded or adoptively transferred Tregs reduced microglia activation and neovascularisation in this animal model (Deliyanti et al., 2017).

4.5.3. MSC, autoantibodies and the complement system

The DR-mediated cell degeneration can induce adaptive immune responses. For instance, auto-antibodies reactive against EC and pericytes have been detected in the serum of patients with diabetes and DR. This correlated to increased concentration of serum complement factors C3a and C5a, but not 4a. These autoantibodies conferred complement-mediated pericyte toxicity (Abcouwer, 2013; McAuley et al., 2014; Paine et al., 2017). Antibody-injured pericytes were also affected in their efficacy to reduce T cell proliferation (Suzuki et al., 2009). Upon disease progression, and due to increased pericyte loss, pericyte-reactive autoantibodies become decreased (McAuley et al., 2014). *In vitro*, hyperglycemic culture increased the susceptibility of pericytes to become attacked. CD38, a known diabetes-associated autoantigen, was upregulated by IFN γ and TNF α and was involved in antibody-dependent pericyte damage (Suzuki et al., 2009).

Complement factors 3a and 5a are chemotactic for MSC and can recruit and retain MSC at sites of injury (Schraufstatter et al., 2009). MSC constitutively secrete the important complement regulatory factor H and constitutively express the three complement regulatory receptors CD46, CD55 and CD59 (Li and Lin, 2012; Tu et al., 2010). Studies showed that MSC can prevent- *via* factor H- complement activation and cell damage (Li et al., 2016a, 2016b; Tu et al., 2010). However, despite expression of these regulatory factors, MSC *per se* can be targeted by the complement system once they are in contact with serum (Li and Lin 2012; Li et al., 2016a, 2016b). This has to be taken into account when planning a therapeutic intervention with MSC, considering local *versus* systemic administration.

5. MSC efficacy in DR

Various adult cell therapies have been explored, *i.e.* CD34 hematopoietic stem/progenitor cells, endothelial progenitor cells and MSC (Lois et al., 2014; Park, 2016). Animal models used to investigate the impact of cell therapy in the context of diabetic retinopathy are summarized in Table 2.

Intravitreal administration of multipotent stromal cells of mesenchymal origin gave encouraging results for the treatment of early phase of DR (Rajashekhhar, 2014). Vascular leakage, apoptosis and inflammation were drastically downregulated. Ezquer et al. focused on the ROS-induced damage to the neurovascular unit of the retina, to find that retinal ganglion cells death was attenuated and neurotrophic factors such as NGF, bFGF and GDNF increased when MSC were injected (Ezquer et al., 2016). Interestingly, the ASC did not acquire neural-like or perivascular-like phenotypes.

A similar localization pattern of ASC was also found in another study after intravitreal injection in oxygen-induced retinopathy (OIR) NOD-SCID mice. In this study, DiI labeled ASC were localized alongside the central retinal microvasculature up to eight weeks after injection,

Table 2
Effects of injected mesenchymal and adipose stromal/stem cells in animal models relevant to diabetic retinopathy.

Animal model	Cell type	Effects	Disease stage	Reference
C57BL/6 mice streptozotocin-injection	2 × 10 ⁵ mouse ASC, passage 2, in 2 µL saline	<ul style="list-style-type: none"> - reduced retinal ganglion cells (RGCs) loss - do not differentiate into neural-like or perivascular-like cells - increased intraocular levels of neurotrophic factors - reduced retinal oxidative damage - no provasculogenic microenvironment changes induced - Extensive reactive gliosis and Inflammation - LCN2 production and activation of STAT3 and ERK in retinal Müller Glia 	NPDR - acellular capillaries - loss of pericytes	(Ezquer et al., 2016)
C57BL/6 mice - Hes5-GFP transgenic mice - Glia fibrillary acidic protein (GFAP)-STAT3-cko	Mouse BM-MSC 1 × 10 ⁵ in 1 µL		NPDR - vasoregression	(Tassoni et al., 2015)
oxygen-induced retinopathy (OIR)/Akimba mouse	hASC, mASC, or hBMSC were suspended in 0.5–1.5 µL of PBS and injected into the vitreous of one eye with a 33G Hamilton needle through the pars plana	<ul style="list-style-type: none"> - ASC migrated and integrated with the retinal vasculature - 16% reduction in avascular area - TGF-β1 enhanced hASC pericyte function 	PDR - retinal ischemia - proliferative vascular damage	(Mendel et al., 2013)
Streptozotocin (STZ) induced diabetic athymic nude rats	ASC 5 × 10 ⁵ –25 × 10 ⁵ of GFP-labeled ASC in 2 µL saline	<ul style="list-style-type: none"> - improved neuronal function (ERG) - alleviated vascular leakage - alleviated apoptosis 	NPDR	(Rajashahkar, 2014)
RCS (RCS-Pp, dystrophic rats with pigment)	1 × 10 ⁵ CM-Dil-labeled rat BMSC in 3 µL of PBS	<ul style="list-style-type: none"> - ASC incorporated into the host vasculature - promoted the proliferation and dedifferentiation of Müller cells - Müller cell dedifferentiation via the NGF induced activation of PI3K and its association with the NGF receptor TrkA 	PDR - microaneurysms - leaky capillaries - capillaries dropout	(Jian et al., 2015)
Akimba mouse	mASC, healthy and diabetic mice	<ul style="list-style-type: none"> - ASC from diabetic sources have an impaired ability to stabilize the microvasculature in diabetic retinopathy → autologous ASC from diabetic patients may not be as effective in protecting against vascular dropout in the retina 	PDR - microaneurysms - leaky capillaries - capillaries dropout	(Cronk et al., 2015b)
oxygen-induced retinopathy	BM-derived myeloid progenitor cells aka EPC	<ul style="list-style-type: none"> - HIF-1α expression is required for myeloid cell-mediated effects in the OIR model 	PDR - retinal ischemia - proliferative vascular damage	(Ritter et al., 2006)
Rats, bilateral intra-cameral (IC) injections of TGF-β	hASC, hBM-MSC and DPSC	<ul style="list-style-type: none"> - Transplanted CD44hi cells differentiate into microglia 		(Mead et al., 2016)
Rat mesenteric model	hASC and hBM-MSC	<ul style="list-style-type: none"> - Microglia participate in retinal vascularization - protected eyes from elevated intraocular pressure-induced loss of RGC function - secrete angiogenic proteins - respond to chemotactic growth factors - pericyte-like phenotypes in response to inflammation <i>in vivo</i> 		(Amos et al., 2011)
NOD mice	BM-MSC	<ul style="list-style-type: none"> - Wnt1 enhanced MSC differentiation into retinal neuron-like cells 		(Xu et al., 2013)
Rat, intraocular pressure (IOP)	Conditioned medium (CM) from rat BM-MSC	<ul style="list-style-type: none"> - protected against functional and histological damage of retinal ischemia - Col1a1 and Col1a2 interactions 		(Dreixler et al., 2014)

adopting a pericyte-like perivascular location and wrapping around vessels. These cells were also positive for the pericytic markers NG2 and alpha-SMA. ASC treatment pre and post induction of OIR reduced avascular areas in the retina, suggesting that even with the time dependent decrease of ASC, modulation of the retinal microenvironment with soluble/paracrine factors may mediate retinal microvessel protection. Of note, having established that ASC can acquire a pericytic phenotype and protect against OIR, the treatment was repeated on Akimba mice, recapitulating the findings of OIR mice (Mendel et al., 2013).

Tassoni and coworkers addressed the potential risks associated with cell injection. They addressed retinal glial responses (graft-induced reactive gliosis) upon intravitreally injected rat BM-MS (Tassoni et al., 2015). Inflammation and extensive reactive gliosis driven by JAK/STAT3 and MAPK cascade were accompanied by macrophage infiltration and retinal detachment upon BM-MS intravitreal transplantation. Müller cells expressing NGF receptor and neurotrophic tyrosine kinase receptor type 1 (TrkA) were observed in the retinas of rats transplanted with rBMSC. Factors downstream of NGF/TrkA signaling, such as p-PI3K, p-Akt and p-CREB, were also increased in Müller cells (Jian et al., 2015).

Cell therapy requires knowledge of the retinal pathological microenvironment prior to cells implantation to be able to ensure safety and efficacy. To this regard, the role of pericytes-EC interaction in the retina has been further elucidated. Partial depletion of pericytes resulted in a lack of spontaneous normalization of pericyte-EC associations in adult animals. Moreover, this caused an inflammatory response and macrophages infiltration, ultimately leading to a negative vascular damage loop via VEGF, PIGF and Ang-2 (Ogura et al., 2017). This study suggests that hyperglycemia alone can initiate the progression of DR, however parallel pathological routes independently and irreversibly damage the retina. In line with this study, the role of ASC-EC communication has been linked to Notch signaling. Specifically, NOTCH2 is a transmembrane ligand which mediates ASC migration and their communication with EC (Terlizzi et al., 2017). Moreover, PDGFR β downregulation was concomitant to NOTCH2 protein downregulation in ASC. Interestingly, hyperglycemia did not quantitatively influence the expression of Notch ligands and receptors in ASC. Modulation of evolutionary conserved mechanisms, such as Notch signaling, might help to reduce the proangiogenic capacity of ASC and maintain their regenerative capacity.

In summary, MSC, specifically ASC exert at least a dual role in DR. First, these seem to resume a pericyte function, acquiring perivascular localization and endothelial cell enwrapping. By this, MSC/ASC appears to adopt pericytic regulatory functions, controlling survival and proliferation. Second, they secrete a variety of trophic factors which modulate the local adverse milieu by regulating oxidative stress, inflammation and integrity of the neurovascular unit. With the exception of the immunomodulatory function, the few animal data existing so far documented that MSC can exert the MoA, we proposed herein. Further studies are needed to elucidate efficacy (and MoA), and the safety/risk profile. Although it is expected that it takes its time to get enough knowledge to be able to move from bench to bedside, we think it is imperative to consider important questions:

- (1) optimal dose and
- (2) route of administration regarding the low survival of transplanted cells,
- (3) choice of animal models to model therapy-relevant DR stages (Fig. 1),
- (4) autologous or allogeneic approach due to impaired potency of MSCs from diabetes (see below),
- (5) safety versus risk of adverse events (cataract, accelerated disease progression due to induced and non-regulated angiogenesis, tumor formation, adverse differentiation),
- (6) identification of MoA (Fig. 2) and establishment of potency assays

to predict therapeutic efficacy
(7) clinical end points to assess the efficacy of MSC therapy.

5.1. Are ASC impaired by diabetes?

The fact that ASC could be easily isolated in a large quantity and with non-invasive procedure, as well as a relatively easily expansion, makes them an impressive suitable candidate for autologous treatment options (Bieback et al., 2012; Moonen et al., 2012; Spiekman et al., 2017; Wuchter et al., 2015). However, in a specific disease context like diabetes, which is well known to affect the metabolism and adipose tissue, it is extremely important to assess whether these cells become affected by the disease. In fact, this would implicate a possible failure and/or impairment of the treatment.

There are contradictory data. Some authors report similar functions and potency, whereas others identified differences between healthy and diabetic donors (Davies et al., 2016; de Lima et al., 2016; Ko et al., 2015; Yaochite et al., 2016). Many studies investigated phenotypical and functional differences between healthy and diabetic ASC, mostly isolated from animal models (Cianfarani et al., 2013; Cronk et al., 2015b; Rennert et al., 2014). Cianfarani et al. observed differences in the expression of ASC markers in the stromal vascular fraction (SVF) isolated from diabetic mice fat pads, suggesting that a depletion of ASC can reflect their reduced survival and the functional impairment in secreting VEGF, HGF and IGF-1. Moreover, skin wounds treated with diabetic SVF resulted in reduced efficacies in wound healing compared to healthy SVF (Cianfarani et al., 2013).

Rennert et al. isolated ASC from inguinal fat pads of STZ C57BL mice and demonstrated their impaired angiogenic potential both *in vitro* and *in vivo*. In fact, ASC failed to induce tube like structures in coculture with HUVEC, although they assumed a perivascular position. This effect was also recapitulated *in vivo*, where gel plugs seeded with diabetic ASC and implanted in healthy mice, displayed significantly reduced levels of vascularization compared with healthy ASC. The authors also analyzed the composition of the freshly isolated SVF. As previously stated, they found a depletion of the global ASC population (here described as a CD45-CD31-CD34+ subpopulation of the SVF) (Rennert et al., 2014).

Similar findings regarding the impairment of the angiogenic potential were also assessed in model of DR (Cronk et al., 2015a). While healthy ASC were able to improve vascular length density and numbers of branch points in the superficial vascular plexus of the retina of Akimba mice, diabetic ASC failed, although they reached the perivascular location. Analysis of cell bioenergetics revealed that healthy and diabetic ASC had a comparable rate of basal, ATP-dependent, uncoupled and non-mitochondrial respiration.

Systems biologists contributed significantly to our understanding of metabolic shifts in diseases such as diabetes. Mardinoglu and Nielsen found that respiratory metabolism was significantly reduced in abdominal fat tissues of diabetic patients (Mardinoglu and Nielsen, 2015). Consequently, oxidated triacylglycerols were linked to slower dynamics of lipid molecules in the patients affected by diabetes. Mitochondrial pyruvate carrier 1 and 2 (MPC1-2) were strongly reduced in diabetic patients. Consequently, acetyl-CoA, central metabolite for biosynthesis of fatty acids, isoprenoids and involved in processes including protein prenylation and N-glycosylation, was also reduced (Pearce et al., 2013). The authors concluded that limitation of condensation of oxaloacetate (OAA) which in turn, downregulated pyruvate and acetyl-CoA, interrupted tricarboxylic acid (TCA) cycle leading to mitochondrial dysfunction (Mardinoglu et al., 2014).

The prolonged exposure of ASC to hyperglycemia and the consequences caused by the associated oxidative stress, formation of ROS and AGEs such as inflammation likely contribute to their dysfunction such as their disturbed protective capacity in angiogenesis. Although, the underlying mechanisms are poorly understood, dysfunctional ASC from diabetics could be partially normalized by augmenting their capacity to clear AGEs *i.e.* via genetical modification with methylglyoxal-

metabolizing enzyme glyoxalase-1 (GLO-1). Introduction of GLO-1 augmented the viability, migration and proangiogenic capacity of ASCs from diabetics. Moreover, in an STZ BALB/c mice model of limb ischemia, Glo-1 expressing ASC restored blood reperfusion, with an overall effect comparable to healthy ASC (Peng et al., 2017).

The alternative to an autologous setting are allogeneic MSCs. In a variety of clinical settings, MSCs have been derived from allogeneic donors (without HLA-matching), mostly based on logistic reasons, rarely based on better efficacy (Ankrum et al., 2014). In a variety of preclinical experiments, human cells have been applied to animal models of DR with signs of efficacy. In these models, no adverse events, including alloreactivity/xenoreactivity have been reported so far. Since MSC application in DR in general is still in its infancy, safety aspects have to be well defined first before discussing autologous *versus* allogeneic use and HLA-matching or mismatching. As for a proper timing, very early DR preferentially needs systemic rather than local administration, with a safety profile in the range comparable to general anti-diabetic and antihypertensive drugs, while routes of administration may change with disease progression (Griffin et al., 2016).

6. The future of cell therapy?

As example of novel concepts, the next generation approaches may involve differentiation of cells before transplantation into the retina, as shown for age-related macular degeneration (AMD) (Kuriyan et al., 2017). Embryonic stem cells (ESC) differentiated to a cone phenotype survived and matured within a model of advanced retinal degeneration. Cell differentiation involved a controlled inhibition of Notch pathway to enhance cone differentiation. Inhibition or activation of specific signaling proteins involved in MSC differentiation might hold the key to effective cell-therapy. For example, retinal cells derived from hESC, migrate, settle and, differentiate into mice retinas. (Lamba et al., 2009). Furthermore, hESC-derived retinæ have been demonstrated to engraft and matured in two different primate models of retinal degeneration (Shirai et al., 2016). A similar concept, but different approach, seeds mouse induced pluripotent stem cells (miPSCs) cultured in a 3D retinal tissue *in vitro* (Assawachananont et al., 2014). Subsequent to transplantation into the sub-retinal space, iPSCs were able to reconstruct the outer nuclear layer of the retina in an advanced model of retinal degeneration. However, another study that combined the transplantation of human retinal pericytes (hRPCs) and human BM-MS-C in a rat model of retinal degeneration, showed great improvements in the overall health of the retinas. Integration and migration of both transplants increased compared to single cells transplantation. Importantly, activation of microglia and the gliosis of Müller cells were suppressed indicating an effective immunomodulatory effect (Qu et al., 2017).

Both human and murine autologous cells used for transplantation have been reported to selectively differentiate and integrate in the retinal microenvironment (Hirami et al., 2009; Ikeda et al., 2005). Meyer et al. demonstrated that human iPSC can generate retina-specific cell types, setting the bases for studying molecular mechanisms involved in cell-differentiation (Meyer et al., 2009).

Besides this targeted differentiation, other approaches investigate whether local cell injection is needed or whether systemic infusion followed by local homing or even systemic effects may be efficacious. In other disease entities, conditioned medium or extracellular vesicles/exosomes were as efficient as direct cell injections (Marote et al., 2016). Intraperitoneal infusion was able to prevent experimentally induced autoimmune uveitis by altering the Th1/Th17 response (Oh et al., 2014).

7. Clinical trials

To date, investigations of MSC therapy in patients with DR are missing. There are a few cell therapy trials investigating intravitreal cell injections. A phase I clinical trial to assess the feasibility and safety of

intravitreal injection of autologous CD34+ BM-cells is currently enrolling participants (NCT01736059). A first-in-human study to examine the safety of an intravitreal injection of autologous BM-MS-C has been published recently (Satarian et al., 2017). The patients in this study had advanced retinitis pigmentosa and were treated with 10⁶ BM-MS-C per 0.1 mL behind the limbus in the phakic and pseudophakic eyes. This pilot resulted in a temporary improvement in perception of light. Three months later, fibrous tissue proliferation was observed with a tractional retinal detachment. Since biopsy could not be obtained from patients, MSC were transplanted in mice to investigate the shift in the cellular microenvironment provoked by the MSC implantation. The authors reported no detection of MSC after ten months. They concluded that MSC lead to macrophage infiltration and retinal folding as reported by others (Tassoni et al., 2015). Autologous ASC have been used for injection to a complementary study (Kuriyan et al., 2017). Although the number of ASC injected was not reported, 60 mL of lipoaspirate was processed to isolate the stem cells. The resulted pellet was resuspended in platelet-rich plasma and immediately used for intravitreal injection in both eyes. The patients in this study had severe visual loss as well as hemorrhagic retinopathy and retinal detachment. The authors concluded that such a complication had to be analyzed from the point of view of cells' preparation rather than the injection procedure. Because of these negative results from these early clinical trials, cell-therapy research is in need of information with regard to safety for human trials. In this respect, several clinical trials are to be initiated (NCT03011541, NCT01920867, NCT01736059). Furthermore, animal models capable of assessing efficacy and risk profile need to be established and careful studies need to be performed, controlling for benefits *versus* risks.

It also has to be taken into account at which disease stage therapy shall be undertaken in terms of a benefit-to-risk assessment. Currently, patients at advanced disease stage receive intravitreal drug injections to slow down progression and prevent vision loss. Accordingly, the benefit-to-risk assessment has to weigh the risk of adverse events *versus* the beneficial effect preventing vision loss. MSC-based cell therapy, however, based on the MoA we summarized above, can be considered as an early treatment option to entirely prevent or delay DR onset and progression to pathological end stages. Here the benefit-to-risk assessment is not yet weighing against vision loss. Accordingly, an extremely careful risk-to-benefit assessment is required, based on more experimental and preclinical models.

8. Conclusion

To date, MSC belong to the most intensely investigated cell types for cell-based therapies. Due to their diverse – and admittedly still incompletely understood – MoAs (Fig. 2), the efficacy of MSCs is challenged in various randomized clinical trials to treat a plethora of diseases. Overall, these trials are phase I safety trials and report that the use of MSCs is safe. Efficacy, nevertheless, remains to be documented. MSC-based therapy for eye diseases is still in its infancy. Preclinical data suggest beneficial effects in retinopathy, including DR. As mentioned before, more data are needed to be able to perform a thorough risk-to-benefit assessment prior to clinical trials and in bench-to-bedside-and-back approaches. Only these will help to understand potential risks and relevant, and possibly disease-stage dependent mode of action.

This review discusses the potential mode of action of MSC in DR (Fig. 2), highlights that a delicate interplay between the different cell types and the diabetic microenvironment needs to be taken into consideration, and requires appropriate models.

In DR, there is preclinical evidence that MSC

- 1) adopt pericyte functions regulation vascular proliferation and survival,
- 2) secrete trophic factors in favor of a proregenerative shift within the

micromilieu,

3) reduce oxidative stress.

The regulation of immune/inflammatory responses to expand favorable phenotypes (M2 macrophages and Treg respectively) has not been shown yet and may relate rather to systemic than local effects in the immunoprivileged retina.

The complexity of diabetic microvascular complications, together with the limitation of animal models and, not yet proven safety for human clinical trials, requires a careful analysis from fundamental biology to patients' susceptibility to improve cell therapy.

Funding

This work has been supported by the Deutsche Forschungsgemeinschaft (GRK 1874/1 DIAMICOM). This project has received funding from the Marie Curie International Research Staff Exchange Scheme with the 7th European Community Framework Program under grant agreement No. 295185 – EULAMDIMA.

Conflicts of interest

The authors confirm that there are no known conflicts of interest associated with this publication.

References

Abcouwer, S.F., 2011. Neural inflammation and the microglial response in diabetic retinopathy. *J. Ocul. Biol. Dis. Infor.* 4, 25–33.

Abcouwer, S.F., 2013. Angiogenic factors and cytokines in diabetic retinopathy. *J. Clin. Cell. Immunol.* <http://dx.doi.org/10.4172/2155-9899>.

Aiello, L.P., DCCT/EDIC Research Group, 2014. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. *Diabetes Care* 37, 17–23.

Aikawa, E., Fujita, R., Asai, M., Kaneda, Y., Tamai, K., 2016. Receptor for advanced glycation end products-mediated signaling impairs the maintenance of bone marrow mesenchymal stromal cells in diabetic model mice. *Stem Cells Dev.* 25 (November (22)), 1721–1732 Epub 2016 Sep 30.

Ajibade, A.A., Wang, Q., Cui, J., Zou, J., Xia, X., Wang, M., Tong, Y., Hui, W., Liu, D., Su, B., Wang, H.Y., Wang, R.F., 2012. TAK1 negatively regulates NF- κ B and p38 MAP kinase activation in Gr-1⁺CD11b⁺ neutrophils. *Immunity* 36 (January (1)), 43–54.

Amos, P.J., Mulvey, C.L., Seaman, S.A., Walpole, J., Degen, K.E., Shang, H., et al., 2011. Hypoxic culture and in vivo inflammatory environments affect the assumption of pericyte characteristics by human adipose and bone marrow progenitor cells. *Am. J. Physiol. Cell. Physiol.* 301, C1378–C1388.

An, X., Li, L., Chen, Y., Luo, A., Ni, Z., Liu, J., Yuan, Y., Shi, M., Chen, B., Long, D., Cheng, J., Lu, Y., 2016. Mesenchymal Stem Cells Ameliorated Glucolipotoxicity in HUVECs through TSG-6. *Int. J. Mol. Sci.* 17 (April (4)), 483.

Ankrum, J.A., Ong, J.F., Karp, J.M., 2014. Mesenchymal stem cells: immune evasive, not immune privileged. *Nat. Biotechnol.* 32, 252–260.

Armulik, A., Genové, G., Betsholtz, C., 2011. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. *Dev. Cell* 21 (August (2)), 193–215.

Assawachananont, J., Mandai, M., Okamoto, S., Yamada, C., Eiraku, M., Yonemura, S., et al., 2014. Transplantation of embryonic and induced pluripotent stem cell-derived 3D retinal sheets into retinal degenerative mice. *Stem Cell. Rep.* 2, 662–674.

Bajek, A., Gurtowska, N., Olkowska, J., Kazmierski, L., Maj, M., Drewa, T., 2016. Adipose-derived stem cells as a tool in cell-based therapies. *Arch. Immunol. Ther. Exp. (Warsz.)* 64, 443–454.

Barber, A.J., Antonetti, D.A., Kern, T.S., Reiter, C.E., Soans, R.S., Krady, J.K., et al., 2005. The Ins2Akita mouse as a model of early retinal complications in diabetes. *Invest. Ophthalmol. Vis. Sci.* 46, 2210–2218.

Bassi, E.J., Moraes-Vieira, P.M., Moreira-Sa, C.S., Almeida, D.C., Vieira, L.M., Cunha, C.S., et al., 2012. Immune regulatory properties of allogeneic adipose-derived mesenchymal stem cells in the treatment of experimental autoimmune diabetes. *Diabetes* 61, 2534–2545.

Benvenuto, F., Ferrari, S., Gerdoni, E., Gualandi, F., Frassoni, F., Pistoia, V., et al., 2007. Human mesenchymal stem cells promote survival of T cells in a quiescent state. *Stem Cells* 25, 1753–1760.

Bieback, K., Kern, S., Kluter, H., Eichler, H., 2004. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. *Stem Cells* 22, 625–634.

Bieback, K., Wuchter, P., Besser, D., Franke, W., Becker, M., Ott, M., et al., 2012. Mesenchymal stromal cells (MSCs): science and f(r)iction. *J. Mol. Med. (Berl.)* 90, 773–782.

Blogowski, W., Bodnarczuk, T., Starzynska, T., 2016. Concise review: pancreatic cancer and bone marrow-derived stem cells. *Stem Cells Transl. Med.* 5, 938–945.

Bourin, P., Bunnell, B.A., Casteilla, L., Dominici, M., Katz, A.J., March, K.L., et al., 2013.

Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). *Cytotherapy* 15, 641–648.

Brownlee, M., 2000. Negative consequences of glycation. *Metab. Clin. Exp.* 49, 9–13.

Brownlee, M., 2005. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes* 54, 1615–1625.

Cammarota, F., Laukkanen, M.O., 2016. Mesenchymal stem/stromal cells in stromal evolution and cancer progression. *Stem Cells Int* 2016, 4824573.

Cao, Y.L., Zhang, F.Q., Hao, F.Q., 2016. Th1/Th2 cytokine expression in diabetic retinopathy. *Genet. Mol. Res.* 15. <http://dx.doi.org/10.4238/gmr.15037311>.

Capitao, M., Soares, R., 2016. Angiogenesis and inflammation crosstalk in diabetic retinopathy. *J. Cell. Biochem.* 117, 2443–2453.

Caplan, A.L., 2008. All MSCs are pericytes? *Cell Stem Cell* 3, 229–230.

Caplan, A.L., 2017. New MSC: MSCs as pericytes are Sentinels and gatekeepers. *J. Orthop. Res.* 35, 1151–1159.

Chen, W., Zhao, M., Zhao, S., Lu, Q., Ni, L., Zou, C., et al., 2017. Activation of the TXNIP/NLRP3 inflammasome pathway contributes to inflammation in diabetic retinopathy: a novel inhibitory effect of minocycline. *Inflamm. Res.* 66, 157–166.

Cianfarani, F., Toietta, G., Di Rocco, G., Cesareo, E., Zambruno, G., Oodorio, T., 2013. Diabetes impairs adipose tissue-derived stem cell function and efficiency in promoting wound healing. *Wound Repair Regen.* 21, 545–553.

Crisan, M., Yap, S., Casteilla, L., Chen, C.W., Corselli, M., Park, T.S., et al., 2008. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* 3, 301–313.

Cronk, S.M., Kelly-Goss, M.R., Ray, H.C., Mendel, T.A., Hoehn, K.L., Bruce, A.C., et al., 2015a. Adipose-derived stem cells from diabetic mice show impaired vascular stabilization in a murine model of diabetic retinopathy. *Stem Cells Transl. Med.* 4, 459–467.

Cronk, S.M., Kelly-Goss, M.R., Ray, H.C., Mendel, T.A., Hoehn, K.L., Bruce, A.C., et al., 2015b. Adipose-derived stem cells from diabetic mice show impaired vascular stabilization in a murine model of diabetic retinopathy. *Stem Cells Transl. Med.* 4, 459–467.

da Silva Meirelles, L., de Deus Wagatsuma, V.M., Malta, T.M., Bonini Palma, P.V., Araujo, A.G., Panepucci, R.A., et al., 2016. The gene expression profile of non-cultured, highly purified human adipose tissue pericytes: transcriptomic evidence that pericytes are stem cells in human adipose tissue. *Exp. Cell Res.* 349, 239–254.

DCCT/EDIC Research Group, Nathan, D.M., Bebu, L., Hainsworth, D., Klein, R., Tamborlane, W., et al., 2017. Frequency of evidence-based screening for retinopathy in type 1 diabetes. *N. Engl. J. Med.* 376, 1507–1516.

Davies, L.C., Alm, J.J., Heldring, N., Moll, G., Gavin, C., Batsis, I., et al., 2016. Type 1 diabetes mellitus donor mesenchymal stromal cells exhibit comparable potency to healthy controls in vitro. *Stem Cells Transl. Med.* 5, 1485–1495.

Deliyanti, D., Talia, D.M., Zhu, T., Maxwell, M.J., Agrotis, A., Jerome, J.R., Hargreaves, E.M., Gerondakis, S., Hibbs, M.L., Mackay, F., Wilkinson-Berka, J.L., 2017. Foxp3⁺ Tregs are recruited to the retina to repair pathological angiogenesis. *Nat. Commun.* 8 (September (1)), 748.

Diaz-Flores, L., Gutierrez, R., Madrid, J.F., Varela, H., Valladares, F., Acosta, E., et al., 2009. Pericytes. Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. *Histol. Histopathol.* 24, 909–969.

Doepfner, T.R., Herz, J., Gorgens, A., Schlechter, J., Ludwig, A.K., Radtke, S., et al., 2015. Extracellular vesicles improve post-stroke neuroregeneration and prevent post-ischemic immunosuppression. *Stem Cells Transl. Med.* 4, 1131–1143.

Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause, D., et al., 2006. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. *Cytotherapy* 8, 315–317.

Dreixler, J.C., Poston, J.N., Balyasnikova, I., Shaikh, A.R., Tupper, K.Y., Conway, S., et al., 2014. Delayed administration of bone marrow mesenchymal stem cell conditioned medium significantly improves outcome after retinal ischemia in rats. *Invest. Ophthalmol. Vis. Sci.* 55, 3785–3796.

Ebert, R., Ulmer, M., Zeck, S., Meissner-Weigl, J., Schneider, D., Stopper, H., Schupp, N., Kassem, M., Jakob, F., 2006. Selenium supplementation restores the antioxidative capacity and prevents cell damage in bone marrow stromal cells in vitro. *Stem Cells* 24 (May (5)), 1226–1235.

Engela, A.U., Hoogduijn, M.J., Boer, K., Litjens, N.H., Betjes, M.G., Weimar, W., et al., 2013. Human adipose-tissue derived mesenchymal stem cells induce functional de novo regulatory T cells with methylated FOXP3 gene DNA. *Clin. Exp. Immunol.* 173, 343–354.

English, K., Ryan, J.M., Tobin, L., Murphy, M.J., Barry, F.P., Mahon, B.P., 2009. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4⁺CD25(high) forkhead box P3⁺ regulatory T cells. *Clin. Exp. Immunol.* 156, 149–160.

Ezquer, F.E., Ezquer, M.E., Parrau, D.B., Carpio, D., Yanez, A.J., Conget, P.A., 2008. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. *Biol. Blood Marrow Transplant.* 14, 631–640.

Ezquer, F., Ezquer, M., Contador, D., Ricca, M., Simon, V., Conget, P., 2012. The anti-diabetic effect of mesenchymal stem cells is unrelated to their transdifferentiation potential but to their capability to restore Th1/Th2 balance and to modify the pancreatic microenvironment. *Stem Cells* 30, 1664–1674.

Ezquer, F., Ezquer, M., Arango-Rodriguez, M., Conget, P., 2014. Could donor multipotent mesenchymal stromal cells prevent or delay the onset of diabetic retinopathy? *Acta Ophthalmol.* 92, e86–95.

Ezquer, F., Giraud-Billoud, M., Carpio, D., Cabezas, F., Conget, P., Ezquer, M., 2015. Proregenerative microenvironment triggered by donor mesenchymal stem cells

- preserves renal function and structure in mice with severe diabetes mellitus. *Biomed. Res. Int.* 2015, 164703.
- Ezquer, M., Urzua, C.A., Montecino, S., Leal, K., Conget, P., Ezquer, F., 2016. Intravitreal administration of multipotent mesenchymal stromal cells triggers a cytoprotective microenvironment in the retina of diabetic mice. *Stem Cell. Res. Ther.* 7, 42. <http://dx.doi.org/10.1186/s13287-016-0299-y>.
- Fang, Y., Tian, X., Bai, S., Fan, J., Hou, W., Tong, H., et al., 2012. Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. *Int. J. Mol. Med.* 30, 85–92.
- Favaro, E., Carpanetto, A., Lamorte, S., Fusco, A., Caorsi, C., Deregiibus, M.C., et al., 2014. Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. *Diabetologia* 57, 1664–1673.
- Friedenstein, A.J., Chailakhjan, R.K., Lalykina, K.S., 1970. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet.* 3, 393–403.
- Gao, X., Song, L., Shen, K., Wang, H., Qian, M., Niu, W., et al., 2014. Bone marrow mesenchymal stem cells promote the repair of islets from diabetic mice through paracrine actions. *Mol. Cell. Endocrinol.* 388, 41–50.
- Gaur, M., Dobke, M., Lunyak, V.V., 2017. Mesenchymal stem cells from adipose tissue in clinical applications for dermatological indications and skin aging. *Int. J. Mol. Sci.* 18.
- Ghoochani, A., Schwarz, M.A., Yakubov, E., Engelhorn, T., Doerfler, A., Buchfelder, M., et al., 2016. MIF-CD74 signaling impedes microglial M1 polarization and facilitates brain tumorigenesis. *Oncogene* 35, 6246–6261.
- Giacco, F., Brownlee, M., 2010. Oxidative stress and diabetic complications. *Circ. Res.* 107, 1058–1070.
- Gordon, S., Martinez, F.O., 2010. Alternative activation of macrophages: mechanism and functions. *Immunity* 32, 593–604.
- Griffin, T.P., Martin, W.P., Islam, N., O'Brien, T., Griffin, M.D., 2016. The promise of mesenchymal stem cell therapy for diabetic kidney disease. *Curr. Diab. Rep.* 16, 42.
- Guimaraes-Camboa, N., Cattaneo, P., Sun, Y., Moore-Morris, T., Gu, Y., Dalton, N.D., et al., 2017. Pericytes of multiple organs do not behave as mesenchymal stem cells in vivo. *Cell Stem Cell* 20, 345–359 e5.
- Guzman, D.C., Olguin, H.J., Garcia, E.H., Peraza, A.V., de la Cruz, D.Z., Soto, M.P., 2017. Mechanisms involved in the development of diabetic retinopathy induced by oxidative stress. *Redox Rep.* 22, 10–16.
- Haddad, R., Saldanha-Araujo, F., 2014. Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: what do we know so far? *BioMed Res. Int.* 216806.
- Hajmoussa, G., Elorza, A.A., Nies, V.J., Jensen, E.L., Nagy, R.A., Harmsen, M.C., 2016. Hyperglycemia induces bioenergetic changes in adipose-derived stromal cells while their pericytic function is retained. *Stem Cells Dev.* 25, 1444–1453.
- Hammes, H.P., Weiss, A., Hess, S., Araki, N., Horiuchi, S., Brownlee, M., et al., 1996. Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. *Lab. Invest.* 75, 325–338.
- Hammes, H.P., Lin, J., Renner, O., Shani, M., Lundqvist, A., Betsholtz, C., et al., 2002. Pericytes and the pathogenesis of diabetic retinopathy. *Diabetes* 51, 3107–3112.
- Hammes, H., Feng, Y., Pfister, F., Brownlee, M., 2011a. Diabetic retinopathy: targeting vasoregression. *Diabetes* 60, 9–16.
- Hammes, H., Feng, Y., Pfister, F., Brownlee, M., 2011b. Diabetic retinopathy: targeting vasoregression. *Diabetes* 60, 9–16.
- Hammes, H.P., 2005. Pericytes and the pathogenesis of diabetic retinopathy. *Horm. Metab. Res.* 37 (Suppl. 1), 39–43.
- Hammes, H.P., 2018. Diabetic retinopathy: hyperglycaemia, oxidative stress and beyond. *Diabetologia* 61, 29–38.
- Hardy, W.R., Moldovan, N.I., Moldovan, L., Livak, K.J., Datta, K., Goswami, C., et al., 2017. Transcriptional networks in single perivascular cells sorted from human adipose tissue reveal a hierarchy of mesenchymal stem cells. *Stem Cells* 35, 1273–1289.
- Harrison, W.W., Bearse Jr., M.A., Ng, J.S., Jewell, N.P., Barez, S., Burger, D., et al., 2011. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. *Invest. Ophthalmol. Vis. Sci.* 52, 772–777.
- Herrera, G.A., Zeng, C., Turbat-Herrera, E.A., Teng, J., 2016. Healing the damaged mesangium in nodular glomerulosclerosis using mesenchymal stem cells (MSCs): expectations and challenges. *Ultrastruct. Pathol.* 40, 61–70.
- Herrmann, M., Bara, J.J., Sprecher, C.M., Menzel, U., Jalowiec, J.M., Osinga, R., et al., 2016. Pericyte plasticity – comparative investigation of the angiogenic and multilineage potential of pericytes from different human tissues. *Eur. Cell. Mater.* 31, 236–249.
- Hirami, Y., Osakada, F., Takahashi, K., Okita, K., Yamanaka, S., Ikeda, H., et al., 2009. Generation of retinal cells from mouse and human induced pluripotent stem cells. *Neurosci. Lett.* 458, 126–131.
- Ho, J.H., Tseng, T.C., Ma, W.H., Ong, W.K., Chen, Y.F., Chen, M.H., et al., 2012. Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and beta-cell differentiation in streptozotocin-induced diabetic mice. *Cell Transplant.* 21, 997–1009.
- Huang, L., Xu, W., Xu, G., 2013. Transplantation of CX3CL1-expressing mesenchymal stem cells provides neuroprotective and immunomodulatory effects in a rat model of retinal degeneration. *Ocul. Immunol. Inflamm.* 21, 276–285.
- Ikeda, H., Osakada, F., Watanabe, K., Mizuseki, K., Haraguchi, T., Miyoshi, H., et al., 2005. Generation of Rx+/Pax6+ neural retinal precursors from embryonic stem cells. *Proc. Natl. Acad. Sci. U. S. A.* 102, 11331–11336.
- Jaimes, Y., Naaldijk, Y., Wenk, K., Leovsky, C., Emrich, F., 2017. Mesenchymal stem cell-derived microvesicles modulate lipopolysaccharides-induced inflammatory responses to microglia cells. *Stem Cells* 35, 812–823.
- Jeong, S.G., Cho, G.W., 2015. Endogenous ROS levels are increased in replicative senescence in human bone marrow mesenchymal stromal cells. *Biochem. Biophys. Res. Commun.* 460 (May (4)), 971–976.
- Jian, Q., Li, Y., Yin, Z.Q., 2015. Rat BMSCs initiate retinal endogenous repair through NGF/TrkA signaling. *Exp. Eye Res.* 132, 34–47.
- Joerger-Messlerli, M.S., Marx, C., Oppliger, B., Mueller, M., Surbek, D.V., Schoeberlein, A., 2016. Mesenchymal stem cells from Wharton's jelly and amniotic fluid. *Best Pract. Res. Clin. Obstet. Gynaecol.* 31, 30–44.
- Karlstetter, M., Scholz, R., Rutar, M., Wong, W.T., Provis, J.M., Langmann, T., 2015. Retinal microglia: just bystander or target for therapy? *Prog. Retin. Eye Res.* 45, 30–57.
- Kern, S., Eichler, H., Stoeve, J., Kluter, H., Bieback, K., 2006. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells* 24, 1294–1301.
- Kim, S., Kwon, J., 2013. COMP-Ang1 inhibits apoptosis as well as improves the attenuated osteogenic differentiation of mesenchymal stem cells induced by advanced glycation end products. *Biochim. Biophys. Acta* 1830, 4928–4934.
- Kim, B.J., Jin, H.K., Bae, J.S., 2011. Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy. *Lab. Anim. Res.* 27, 171–176.
- Kim, K.H., Blasco-Morente, G., Cuende, N., Arias-Santiago, S., 2017. Mesenchymal stromal cells: properties and role in management of cutaneous diseases. *J. Eur. Acad. Dermatol. Venereol.* 31, 414–423.
- Ko, E., Lee, K.Y., Hwang, D.S., 2012. Human umbilical cord blood-derived mesenchymal stem cells undergo cellular senescence in response to oxidative stress. *Stem Cells Dev.* 21 (July (11)), 1877–1886.
- Ko, K.I., Coimbra, L.S., Tian, C., Alblowi, J., Kayal, R.A., Einhorn, T.A., et al., 2015. Diabetes reduces mesenchymal stem cells in fracture healing through a TNFalpha-mediated mechanism. *Diabetologia* 58, 633–642.
- Ko, J.H., Leea, H.J., Jeonga, H.J., Kima, M.K., Weea, W.R., Yoona, S., et al., 2016. Mesenchymal stem-stromal cells precondition lung monocytes-macrophages to produce tolerance against allo- and autoimmunity in the eye. *PNAS* 113, 158–163.
- Koliarakis, V., Pallangyo, C.K., Greten, F.R., Kollias, G., 2017. Mesenchymal cells in colon cancer. *Gastroenterology* 152, 964–979.
- Kowluru, R.A., Chan, P.S., 2007. Oxidative stress and diabetic retinopathy. *Exp. Diabetes Res.* 2007, 43603.
- Kowluru, R.A., Mishra, M., 2015. Oxidative stress, mitochondrial damage and diabetic retinopathy. *Biochim. Biophys. Acta* 1852, 2474–2483.
- Kume, S., Kato, S., Yamagishi, S., Inagaki, Y., Ueda, S., Arima, N., Okawa, T., Kojiro, M., Nagata, K., 2005. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. *J. Bone Miner. Res.* 20 (September (9)), 1647–1658.
- Kuriyan, A.E., Albin, T.A., Townsend, J.H., Rodriguez, M., Pandya, H.K., Leonard 2nd, R.E., et al., 2017. Vision loss after intravitreal injection of autologous stem cells for AMD. *N. Engl. J. Med.* 376, 1047–1053.
- Lamba, D.A., Gust, J., Reh, T.A., 2009. Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice. *Cell Stem Cell* 4, 73–79.
- Le Blanc, Katarina, Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., et al., 2004. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet* 363, 1439–1441.
- Le Blanc, Katarina, Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., et al., 2008. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet* 371, 1579–1586.
- Lee, R.H., Seo, M.J., Reger, R.L., Spees, J.L., Pulini, A.A., Olson, S.D., et al., 2006. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. *Proc. Natl. Acad. Sci. U. S. A.* 103, 17438–17443.
- Li, Y., Lin, F., 2012. Mesenchymal stem cells are injured by complement after their contact with serum. *Blood* 120, 3436–3443.
- Li, Y., Fung, J., Lin, F., 2016a. Local inhibition of complement improves mesenchymal stem cell viability and function after administration. *Mol. Ther.* 24, 1665–1674.
- Li, Y., Qiu, W., Zhang, L., Fung, J., Lin, F., 2016b. Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage. *Biomaterials* 102, 209–219.
- Li, C., Miao, X., Li, F., Wang, S., Liu, Q., Wang, Y., et al., 2017a. Oxidative stress-related mechanisms and antioxidant therapy in diabetic retinopathy. *Oxid. Med. Cell. Longev.* 9702820.
- Li, X., Zarbin, M.A., Bhagat, N., 2017b. Anti-vascular endothelial growth factor injections: the new standard of care in proliferative diabetic retinopathy? *Dev. Ophthalmol.* 60, 131–142.
- Liochev, S.I., Fridovich, I., 1999. Superoxide and iron: partners in crime. *IUBMB Life* 48, 157–161.
- Lois, N., McCarter, R.V., O'Neill, C., Medina, R.J., Stitt, A.W., 2014. Endothelial progenitor cells in diabetic retinopathy. *Front. Endocrinol. (Lausanne)* 5, 44.
- Luz-Crawford, P., Kurte, M., Bravo-Alegria, J., Contreras, R., Nova-Lamperti, E., Tejedor, G., et al., 2013. Mesenchymal stem cells generate a CD4+ CD25+ Foxp3+ regulatory T cell population during the differentiation process of Th1 and Th17 cells. *Stem Cell Res. Ther.* 4, 1–12.
- Lv, S., Cheng, J., Sun, A., Li, J., Wang, W., Guan, G., et al., 2014. Mesenchymal stem cells transplantation ameliorates glomerular injury in streptozotocin-induced diabetic nephropathy in rats via inhibiting oxidative stress. *Diabetes Res. Clin. Pract.* 104, 143–154.
- Ma, Q., Shen, J.H., Shen, S.R., Das, U.N., 2014. Bioactive lipids in pathological retinopathy. *Crit. Rev. Food Sci. Nutr.* 54, 1–16.
- Maccario, R., Podestà, M., Moretta, A., Cometa, A., Comoli, P., Montagna, D., et al., 2005. Interaction of human mesenchymal stem cells with cells involved in alloantigen-

- specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. *Haematologica* 90, 516–525.
- Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., 2002. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Trends Immunol.* 23, 549–555.
- Mardinoglu, A., Nielsen, J., 2015. New paradigms for metabolic modeling of human cells. *Curr. Opin. Biotechnol.* 34, 91–97.
- Mardinoglu, A., Kampf, C., Asplund, A., Fagerberg, L., Hallstrom, B.M., Edlund, K., et al., 2014. Defining the human adipose tissue proteome to reveal metabolic alterations in obesity. *J. Proteome Res.* 13, 5106–5119.
- Marote, A., Teixeira, F.G., Mendes-Pinheiro, B., Salgado, A.J., 2016. MSCs-derived exosomes: cell-secreted nanovesicles with regenerative potential. *Front. Pharmacol.* 7, 231.
- Martinez-Zapata, M.J., Marti-Carvajal, A.J., Sola, I., Pijoan, J.I., Buil-Calvo, J.A., Cordero, J.A., et al., 2014. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. *Cochrane Database Syst. Rev.* CD008721.
- McAuley, A.K., Sanfilippo, P.G., Hewitt, A.W., Liang, H., Lamoureux, E., Wang, J.J., et al., 2014. Vitreous biomarkers in diabetic retinopathy: a systematic review and meta-analysis. *J. Diabetes Complications* 28, 419–425.
- Mead, B., Hill, L.J., Blanch, R.J., Ward, K., Logan, A., Berry, M., et al., 2016. Mesenchymal stromal cell-mediated neuroprotection and functional preservation of retinal ganglion cells in a rodent model of glaucoma. *Cytotherapy* 18, 487–496.
- Melcher, M., Danhauser, K., Seibt, A., Degistirici, O., Baertling, F., Kondadi, A.K., et al., 2017. Modulation of oxidative phosphorylation and redox homeostasis in mitochondrial NDUFS4 deficiency via mesenchymal stem cells. *Stem Cell Res. Ther.* 8, 150.
- Melief, S.M., Schrama, E., Brugman, M.H., Tiemessen, M.M., Hoogduijn, M.J., Fibbe, W.E., et al., 2013. Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. *Stem Cells* 31, 1980–1991.
- Mendel, T.A., Clabough, E.B., Kao, D.S., Demidova-Rice, T.N., Durham, J.T., Zotter, B.C., et al., 2009. Pericytes derived from adipose-derived stem cells protect against retinal vasculopathy. *PLoS One* 8, e65691.
- Meyer, J.S., Shearer, R.L., Capowski, E.E., Wright, L.S., Wallace, K.A., McMillan, E.L., et al., 2009. Modeling early retinal development with human embryonic and induced pluripotent stem cells. *Proc. Natl. Acad. Sci. U. S. A.* 106, 16698–16703.
- Milanesi, A., Lee, J.W., Li, Z., Da Sacco, S., Villani, V., Cervantes, V., et al., 2012. Beta-cell regeneration mediated by human bone marrow mesenchymal stem cells. *PLoS One* 7, e42177.
- Mohammadzadeh, A., Pourfathollah, A.A., Shahrokhi, S., Hashemi, S.M., Moradi, S.L., Soleimani, M., 2014. Immunomodulatory effects of adipose-derived mesenchymal stem cells on the gene expression of major transcription factors of T cell subsets. *Int. Immunopharmacol.* 20, 316–321.
- Moonen, J.R., Harmsen, M.C., Krenning, G., 2012. Cellular plasticity: the good, the bad, and the ugly? Microenvironmental influences on progenitor cell therapy. *Can. J. Physiol. Pharmacol.* 90, 275–285.
- Morgan, M.J., Liu, Z.G., 2011. Crosstalk of reactive oxygen species and NF- κ B signaling. *Cell Res.* 21 (January (1)), 103–115.
- Murugeswari, P., Shukla, D., Rajendran, A., Kim, R., Namperumalsamy, P., Muthukaruppan, V., 2008. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. *Retina* 28, 817–824.
- Nagaishi, K., Mizue, Y., Chikenji, T., Otani, M., Nakano, M., Konari, N., et al., 2016. Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. *Sci. Rep.* 6, 34842.
- Najar, M., Raicevic, G., Crompt, E., Fayyad-Kazan, H., Bron, D., Toungouz, M., et al., 2016. The immunomodulatory potential of mesenchymal stromal cells a story of a regulatory network. *J. Immunother.* 39, 45–59.
- Naldini, A., Pucci, A., Bernini, C., Carraro, F., 2003. Regulation of angiogenesis by Th1 and Th2-type cytokines. *Curr. Pharm. Des.* 9, 511–519.
- Navarro, R., Compte, M., Alvarez-Vallina, L., Sanz, L., 2016. Immune regulation by pericytes: modulating innate and adaptive immunity. *Front. Immunol.* 7, 480.
- Nicola, M.D., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P.D., Matteucci, P., et al., 2002. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. *Blood* 99, 3838–3843.
- Ogura, S., Kurata, K., Hattori, Y., Takase, H., Ishiguro-Oonuma, T., Hwang, Y., et al., 2017. Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown. *JCI Insight* 2, e90905.
- Oh, J.Y., Kim, T.W., Jeong, H.J., Lee, H.J., Ryu, J.S., Wee, W.R., et al., 2014. Intraperitoneal infusion of mesenchymal stem/stromal cells prevents experimental autoimmune uveitis in mice. *Mediators Inflamm.* 2014, 624640.
- Okamoto, N., Tobe, T., Hackett, S.F., Ozaki, H., Viores, M.A., LaRochelle, W., et al., 1997. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. *Am. J. Pathol.* 151, 281–291.
- Ophelders, D.R., Wolfs, T.G., Jellema, R.K., Zwanenburg, A., Andriessen, P., Delhaas, T., et al., 2016. Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia. *Stem Cells Transl. Med.* 5, 754–763.
- Oses, C., Olivares, B., Ezquer, M., Acosta, C., Bosch, P., Donoso, M., et al., 2017. Preconditioning of adipose tissue-derived mesenchymal stem cells with deferroxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: potential application in the treatment of diabetic neuropathy. *PLoS One* 12, e0178011.
- Paine, S.K., Mondal, L.K., Borah, P.K., Bhattacharya, C.K., Mahanta, J., 2017. Pro- and antiangiogenic VEGF and its receptor status for the severity of diabetic retinopathy. *Mol. Vis.* 23, 356–363.
- Park, K.S., Kim, Y.S., Kim, J.H., Choi, B., Kim, S.H., Tan, A.H., et al., 2010. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. *Transplantation* 89, 509–517.
- Park, C.M., Kim, M.J., Kim, S.M., Park, J.H., Kim, Z.H., Choi, Y.S., 2016. Umbilical cord mesenchymal stem cell-conditioned media prevent muscle atrophy by suppressing muscle atrophy-related proteins and ROS generation. *In Vitro Cell. Dev. Biol. Anim.* 52, 68–76.
- Park, D.Y., Lee, J., Kim, J., Kim, K., Hong, S., Han, S., et al., 2017. Plastic roles of pericytes in the blood-retinal barrier. *Nat. Commun.* 8, 15296.
- Park, S.S., 2016. Cell therapy applications for retinal vascular diseases: diabetic retinopathy and retinal vein occlusion. *Invest. Ophthalmol. Vis. Sci.* 57, ORSFJ1–ORSFJ10.
- Pearce, E.L., Poffenberger, M.C., Chang, C.H., Jones, R.G., 2013. Fueling immunity: insights into metabolism and lymphocyte function. *Science* 342, 1242454.
- Peng, Z., Yang, X., Qin, J., Ye, K., Wang, X., Shi, H., et al., 2017. Glyoxalase-1 over-expression reverses defective proangiogenic function of diabetic adipose-derived stem cells in streptozotocin-induced diabetic mice model of critical limb ischemia. *Stem Cells Transl. Med.* 6, 261–271.
- Pérez, L.M., Bernal, A., de Lucas, B., San Martín, N., Mastrangelo, A., García, A., Barbas, C., Gálvez, B.G., 2015. Altered metabolic and stemness capacity of adipose tissue-derived stem cells from obese mouse and human. *PLoS One* 10 (April (4)) e0123397.
- Perry, B.C., Zhou, D., Wu, X., Yang, F.C., Byers, M.A., Chu, T.M., et al., 2008. Collection, cryopreservation, and characterization of human dental pulp-derived mesenchymal stem cells for banking and clinical use. *Tissue Eng. Part C Methods* 14, 149–156.
- Peterson, K.M., Aly, A., Lerman, A., Lerman, L.O., Rodriguez-Porcel, M., 2011. Improved survival of mesenchymal stromal cell after hypoxia preconditioning: role of oxidative stress. *Life Sci.* 88, 65–73.
- Phinney, D.G., Sensebe, L., 2013. Mesenchymal stromal cells: misconceptions and evolving concepts. *Cytotherapy* 15, 140–145.
- Phinney, D.G., 2007. Biochemical heterogeneity of mesenchymal stem cell populations: clues to their therapeutic efficacy. *Cell. Cycle* 6, 2884–2889.
- Pistoia, V., Raffaghello, L., 2017. Mesenchymal stromal cells and autoimmunity. *Int. Immunol.* 29, 49–58.
- Preissner, K.T., Kanse, S.M., Hammes, H.P., 1997. Integrin chatter and vascular function in diabetic retinopathy. *Horm. Metab. Res.* 29, 643–645.
- Qin, H.H., Filippi, C., Sun, S., Lehec, S., Dhawan, A., Hughes, R.D., 2015. Hypoxic preconditioning potentiates the trophic effects of mesenchymal stem cells on co-cultured human primary hepatocytes. *Stem Cell Res. Ther.* 6 (December), 237. <http://dx.doi.org/10.1186/s13287-015-0218-7>.
- Qu, L., Gao, L., Xu, H., Duan, P., Zeng, Y., Liu, Y., et al., 2017. Combined transplantation of human mesenchymal stem cells and human retinal progenitor cells into the sub-retinal space of RCS rats. *Sci. Rep.* 7, 199. <http://dx.doi.org/10.1186/s13287-016-0351-y>.
- Rajashekhar, G., 2014. Mesenchymal stem cells: new players in retinopathy therapy. *Front. Endocrinol. (Lausanne)* 5, 59.
- Rakoczy, E.P., Ali Rahman, I.S., Binz, N., Li, C.R., Vagaja, N.N., de Pinho, M., et al., 2010. Characterization of a mouse model of hyperglycemia and retinal neovascularization. *Am. J. Pathol.* 177, 2659–2670.
- Rani, S., Ryan, A.E., Griffin, M.D., Ritter, T., 2015. Mesenchymal stem cell-derived extracellular vesicles: toward cell-free therapeutic applications. *Mol. Ther.* 23, 812–823.
- Ren, M., Yang, S., Li, J., Hu, Y., Ren, Z., Ren, S., 2013. Ginkgo biloba L. extract enhances the effectiveness of syngeneic bone marrow mesenchymal stem cells in lowering blood glucose levels and reversing oxidative stress. *Endocrine* 43, 360–369.
- Rennett, R.C., Sorkin, M., Janusz, M., Duscher, D., Kosaraju, R., Chung, M.T., et al., 2014. Diabetes impairs the angiogenic potential of adipose-derived stem cells by selectively depleting cellular subpopulations. *Stem Cell Res. Ther.* 5, 1–12.
- Ritter, M.R., Banin, E., Moreno, S.K., Aguilar, E., Dorrell, M.I., Friedlander, M., 2006. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. *J. Clin. Invest.* 116, 3266–3276.
- Rossini, A.A., Like, A.A., Chick, W.L., Appel, M.C., Cahill Jr., G.F., 1977. Studies of streptozotocin-induced insulin and diabetes. *Proc. Natl. Acad. Sci. U. S. A.* 74, 2485–2489.
- Sakaguchi, S., Yamaguchi, T., Nomura, T., Ono, M., 2008. Regulatory T cells and immune tolerance. *Cell* 133, 775–787.
- Salgado, A.J., Reis, R.L., Sousa, N., Gimble, J.M., 2010. Adipose tissue derived stem cells secrete soluble factors and their roles in regenerative medicine. *Curr. Stem Cell Res. Ther.* 5, 103–110.
- Santos, A.R., Ribeiro, L., Bandello, F., Lattanzio, R., Egan, C., Frydkjaer-Olsen, U., et al., 2017. Functional and structural findings of neurodegeneration in early stages of diabetic retinopathy: cross-sectional analyses of baseline data of the EUROCONDOR project. *Diabetes* 66, 2503–2510.
- Satarian, L., Nourinia, R., Safi, S., Kanavi, M.R., Jarughi, N., Daftarian, N., et al., 2017. Intravitreal injection of bone marrow mesenchymal stem cells in patients with advanced retinitis pigmentosa; a safety study. *J. Ophthalmic Vis. Res.* 12, 58–64.
- Schraufstatter, I.U., Discipio, R.G., Zhao, M., Khaldooyani, S.K., 2009. C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. *J. Immunol.* 182, 3827–3836.
- Sela, M., Tirza, G., Ravid, O., Volovitz, I., Solodeev, I., Friedman, O., Zipori, D., Gur, E., Krelin, Y., Shani, N., 2015. NOX 1-induced accumulation of reactive oxygen species in abdominal fat-derived mesenchymal stromal cells impinges on long-term proliferation. *Cell Death Dis.* 6 (April), e1728. <http://dx.doi.org/10.1038/cddis.2015.84>.
- Shirai, H., Mandai, M., Matsushita, K., Kuwahara, A., Yonemura, S., Nakano, T., et al., 2016. Transplantation of human embryonic stem cell-derived retinal tissue in two primate models of retinal degeneration. *Proc. Natl. Acad. Sci. U. S. A.* 113, E81–90.

- Sims, D.E., 1986. The pericyte—a review. *Tissue Cell* 18 (2), 153–174.
- Smith, L.E., Wesolowski, E., McLellan, A., Kostyk, S.K., D'Amato, R., Sullivan, R., et al., 1994. Oxygen-induced retinopathy in the mouse. *Invest. Ophthalmol. Vis. Sci.* 35, 101–111.
- Soliman, A.Z., Silva, P.S., Aiello, L.P., Sun, J.K., 2012. Ultra-wide field retinal imaging in detection, classification, and management of diabetic retinopathy. *Semin. Ophthalmol.* 27, 221–227.
- Sordi, V., Malosio, M.L., Marchesi, F., Mercalli, A., Melzi, R., Giordano, T., et al., 2005. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. *Blood* 106, 419–427.
- Spiekman, M., van Dongen, J.A., Willemsen, J.C., Hoppe, D.L., van der Lei, B., Harmsen, M.C., 2017. The power of fat and its adipose-derived stromal cells: emerging concepts for fibrotic scar treatment. *J. Tissue Eng. Regen. Med.* 11 (November (11)), 3220–3235.
- Stitt, A.W., Curtis, T.M., Chen, M., Medina, R.J., McKay, G.J., Jenkins, A., et al., 2016. The progress in understanding and treatment of diabetic retinopathy. *Prog. Retin. Eye Res.* 51, 156–186.
- Stolzing, A., Sellers, D., Llewelyn, O., Scutt, A., 2010. Diabetes induced changes in rat mesenchymal stem cells. *Cells Tissues Organs* 191 (6), 453–465.
- Sukpat, S., Sarasena, N., Wongphoom, J., Patumraj, S., 2013. Vasculoprotective effects of combined endothelial progenitor cells and mesenchymal stem cells in diabetic wound care: their potential role in decreasing wound-oxidative stress. *Biomed. Res. Int.* 2013, 459196.
- Suzuki, S., Tanaka, K., Suzuki, N., 2009. Ambivalent aspects of interleukin-6 in cerebral ischemia: inflammatory versus neurotrophic aspects. *J. Cereb. Blood Flow Metab.* 29, 464–479.
- Takeuchi, M., Sato, T., Tanaka, A., Muraoka, T., Taguchi, M., Sakurai, Y., et al., 2015. Elevated levels of cytokines associated with Th2 and Th17 cells in vitreous fluid of proliferative diabetic retinopathy patients. *PLoS One* 10, e0137358.
- Tassoni, A., Gutteridge, A., Barber, A.C., Osborne, A., Martin, K.R., 2015. Molecular mechanisms mediating retinal reactive gliosis following bone marrow mesenchymal stem cell transplantation. *Stem Cells* 33, 3006–3016.
- Terlizzi, V., Kolibabka, M., Burgess, J.K., Hammes, H.P., Harmsen, M.C., 2017. The pericytic phenotype of adipose tissue-derived stromal cells is promoted by NOTCH2. *Stem Cells*. <http://dx.doi.org/10.1002/stem.2726>. [Epub ahead of print].
- Tian, Z., Li, Y., Ji, P., Zhao, S., Cheng, H., 2013. Mesenchymal stem cells protects hyperoxia-induced lung injury in newborn rats via inhibiting receptor for advanced glycation end-products/nuclear factor kappaB signaling. *Exp. Biol. Med. (Maywood)* 238, 242–247.
- Tomita, M., Adachi, Y., Yamada, H., Takahashi, K., Kiuchi, K., Oyaizu, H., Ikebukuro, K., Kaneda, H., Matsumura, M., Ikehara, S., 2002. Bone marrow-derived stem cells can differentiate into retinal cells in injured rat retina. *Stem Cells* 20 (4), 279–283.
- Traktuev, D.O., Merfeld-Clauss, S., Li, J., Kolonin, M., Arap, W., Pasqualini, R., et al., 2008. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. *Circ. Res.* 102, 77–85.
- Tu, Z., Li, Q., Bu, H., Lin, F., 2010. Mesenchymal stem cells inhibit complement activation by secreting factor H. *Stem Cells Dev.* 19, 1803–1809.
- Tu, Z., Li, Y., Smith, D.S., Sheibani, N., Huang, S., Kern, T., et al., 2011. Retinal pericytes inhibit activated T cell proliferation. *Invest. Ophthalmol. Vis. Sci.* 52, 9005–9010.
- Turrens, J.F., 2003. Mitochondrial formation of reactive oxygen species. *J. Physiol.* 552, 335–344.
- Tyndall, A., 2008. Multipotent mesenchymal stromal cells for autoimmune diseases. *Transfus. Med. Hemother.* 35, 313–318.
- Valle-Prieto, A., Conget, P.A., 2010. Human mesenchymal stem cells efficiently manage oxidative stress. *Stem Cells Dev.* 19, 1885–1893.
- van Dijk, C.G., Nieuweboer, F.E., Pei, J.Y., Xu, Y.J., Burgisser, P., van Mulligen, E., et al., 2015. The complex mural cell: pericyte function in health and disease. *Int. J. Cardiol.* 190, 75–89.
- Virgili, G., Menchini, F., Casazza, G., Hogg, R., Das, R.R., Wang, X., et al., 2015. Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy. *Cochrane Database Syst. Rev.* 1, CD008081.
- Volarevic, V., Al-Qahtani, A., Arsenijevic, N., Pajovic, S., Lukic, M.L., 2010. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. *Autoimmunity* 43, 255–263.
- von Boehmer, H., 2005. Mechanisms of suppression by suppressor T cells. *Nat. Immunol.* 6, 338–344.
- Vujosevic, S., Simo, R., 2017. Local and systemic inflammatory biomarkers of diabetic retinopathy: an integrative approach. *Invest. Ophthalmol. Vis. Sci.* 58, B068–B075.
- Wakabayashi, Y., Usui, Y., Okunuki, Y., Kezuka, T., Takeuchi, M., Goto, H., et al., 2010. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. *Retina* 30, 339–344.
- Wang, J., Lin, J., Schlotterer, A., Wu, L., Fleming, T., Busch, S., et al., 2014. CD74 indicates microglial activation in experimental diabetic retinopathy and exogenous methylglyoxal mimics the response in normoglycemic retina. *Acta Diabetol.* 51, 813–821.
- Williams, G.A., Scott, I.U., Haller, J.A., Maguire, A.M., Marcus, D., McDonald, H.R., 2004. Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology. *Ophthalmology* 111, 1055–1062.
- Wucher, P., Bieback, K., Schrezenmeier, H., Bornhauser, M., Muller, L.P., Bonig, H., et al., 2015. Standardization of good manufacturing practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. *Cytotherapy* 17, 128–139.
- Xu, Y.X., Chen, L., Hou, W.K., Lin, P., Sun, L., Sun, Y., et al., 2009. Mesenchymal stem cells treated with rat pancreatic extract secrete cytokines that improve the glycometabolism of diabetic rats. *Transplant. Proc.* 41, 1878–1884.
- Xu, Y., Gu, Z., Shen, B., Xu, G., Zhou, T., Jiang, J., et al., 2013. Roles of Wnt/beta-catenin signaling in retinal neuron-like differentiation of bone marrow mesenchymal stem cells from nonobese diabetic mice. *J. Mol. Neurosci.* 49, 250–261.
- Xu, H., Cai, M., Zhang, X., 2015. Effect of the blockade of the IL-23-Th17-IL-17A pathway on streptozotocin-induced diabetic retinopathy in rats. *Graefes Arch. Clin. Exp. Ophthalmol.* 253, 1485–1492.
- Xu, J., Gong, T., Heng, B.C., Zhang, C.F., 2017. A systematic review: differentiation of stem cells into functional pericytes. *FASEB J.* 31, 1775–1786.
- Yan, Z., Zhuansun, Y., Chen, R., Li, J., Ran, P., 2014a. Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. *Exp. Cell Res.* 324, 65–74.
- Yan, Z., Zhuansun, Y., Liu, G., Chen, R., Li, J., Ran, P., 2014b. Mesenchymal stem cells suppress T cells by inducing apoptosis and through PD-1/B7-H1 interactions. *Immunol. Lett.* 162, 248–255.
- Yanez-Mo, M., Siljander, P.R., Andreu, Z., Zavec, A.B., Borrás, F.E., Buzas, E.I., et al., 2015. Biological properties of extracellular vesicles and their physiological functions. *J. Extracell. Vesicles* 4, 27066.
- Yang, R., Liu, H., Williams, I., Chaqour, B., 2007. Matrix metalloproteinase-2 expression and apoptogenic activity in retinal pericytes: implications in diabetic retinopathy. *Ann. N. Y. Acad. Sci.* 1103, 196–201.
- Yang, S.H., Park, M.J., Yoon, I.H., Kim, S.Y., Hong, S.H., Shin, J.Y., et al., 2009. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. *Exp. Mol. Med.* 41, 315–324.
- Yaochite, J.N., de Lima, K.W., Caliar-Oliveira, C., Palma, P.V., Couri, C.E., Simoes, B.P., et al., 2016. Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties. *Stem Cell Res. Ther.* 7, 14. <http://dx.doi.org/10.1186/s13287-015-0261-4>.
- Zhang, C., Xiao, C., Wang, P., Xu, W., Zhang, A., Li, Q., et al., 2014. The alteration of Th1/Th2/Th17/Treg paradigm in patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. *Hum. Immunol.* 75, 289–296.
- Zimmerlin, L., Donnenberg, V.S., Rubin, J.P., Donnenberg, A.D., 2013. Mesenchymal markers on human adipose stem/progenitor cells. *Cytometry A* 83 (January (1)), 134–140.
- Zimmermann, K.W., 1923. Der feinere bau der blutcapillares. *Z. Anat. Entwicklungsgesch.* 68, 3–109.
- Zong, H., Ward, M., Madden, A., Yong, P.H., Limb, G.A., Curtis, T.M., et al., 2010. Hyperglycaemia-induced pro-inflammatory responses by retinal Muller glia are regulated by the receptor for advanced glycation end-products (RAGE). *Diabetologia* 53, 2656–2666.